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Infantile hemangioma (IH) is a benign vascular tumor caused by endothelial cell proliferation. 
With a prevalence of about 4%-10% in the first year of life, it is the most common benign tumor 
of infancy1-4. IHs may be located in any region of the body, including the internal organs, but are 
mostly (60%) located in the skin of the head and neck region5,6. The liver is the most common 
extracutaneous site of IHs. Hepatic IHs, which can be focal, multifocal, or diffuse, are the most 
common benign liver tumors of infancy7. IHs are seen 3-5 times more often in females than 
in males. Other risk factors for developing an IH [including their crude odds ratios (OR)] are: 
Caucasian race, low birth weight (OR = 1.8), prematurity (OR = 1.8), family history of IH (OR 
= 2.5), and being born from a multiple birth (OR = 2.2)8-10. Because of their benign and self-
limiting character, no intervention is needed in more than 90% of cases. However, there are 
circumstances that will require treatment during the proliferative phase. These concern infants 
with IHs with a substantial morbidity, such as ulceration, vision loss, breathing difficulties, or 
potential disfigurement because of the tumor location. Until 2008, the treatment of IHs consisted 
of systemic or intralesional corticosteroids or surgery11,12. In 2008, treatment of IH with propranolol 
was reported for the first time13. After that, multiple publications followed, and the approach to 
IHs dramatically changed. This shift in the management of cutaneous IHs has also influenced 
the treatment of hepatic IHs7,14,15. Propranolol is currently considered to be the treatment of first 
choice for IHs. Propranolol has been used for several decades to treat cardiovascular diseases, 
such as hypertension, ischemic heart disease, and arrhythmias in adults and children. Although 
there is an abundance of experience with propranolol in infants, responses to propranolol have 
been far better studied in adults than in children16. Propranolol has its side effects, although 
these are mild compared with previous IH treatments. The shortterm side effects consist of 
hypotension, bradycardia, respiratory symptoms, hypoglycemia, gastrointestinal complaints, 
and cold extremities. The lipophilic nature of propranolol facilitates the crossing of the bloodbrain 
barrier, causing adverse effects such as a sleepy and drowsy feeling during the day and 
restlessness at night17. Based on studies in adult volunteers and animals, it has been postulated 
that there may be longterm side effects of this drug, affecting the developing central nervous 
system, when given to infants18. Our review summarizes the discoveries that have been made 
since 2008 regarding the treatment of IHs with propranolol. It also highlights the most important 
areas that still remain unknown.
1.2 Pathophysiology of infantile hemangioma
Despite its high incidence, the pathophysiology of IH is still unclear. There is no universally 
accepted theory, and no single hypothesis is sufficient to describe and explain all of its features. 




IH endothelial cells share immunohistochemical markers with the placental microvasculature. 
Both possess glucose transporter protein type 1 (GLUT-1), Lewis Y antigen, merosin, 
laminin, chemokine receptor 6, CD15, insulin-like growth factor 2 (IGF-2), and indoleamine 
2,3-dioxygenase. This immunohistochemical profile differentiates IHs from other vascular 
birthmarks or tumors19-22. In addition, there is a high level of genetic similarity between the 
placenta and IH23. Therefore, it was hypothesized that embolization of placental endothelial 
cells to the fetus could play a role in the pathogenesis of IH. This hypothesis was strengthened 
by findings that transcervical chorionic villus sampling is associated with a threefold increased 
incidence of IH and that placental abnormalities, such as abnormal placentation, are associated 
with a higher incidence of IH24-27. However, the latter may also be explained by the hypoxia 
hypothesis. In contrast to the placental embolization theory are the failed attempts to detect the 
presence of maternal–fetal chimerism in IH tissue28.
Angio- and vasculogenesis theory
Both angiogenesis (growth of new blood vessels from pre-existing vessels) and vasculogenesis 
(de novo formation of blood vessels from stem cells) are hypothesized to contribute to IH 
formation. IHs may result from somatic mutations in a gene mediating endothelial cell proliferation 
(growth regulatory pathways)29. Such mutations may alternate the vascular endothelial growth 
factor (VEGF) signaling pathway by reducing the expression of VEGF receptor 1 (VEGFR-1), 
which causes hyperactivity of VEGFR-2 and may induce IH formation through angiogenesis30. 
IGF-2 and basic fibroblast growth factor also stimulate angiogenesis and are upregulated in 
proliferating IHs31,32. Endothelial progenitor cells (EPCs), stem cells of vascular origin that are 
capable of differentiating into endothelial cells, seem to play a role in the development of IH 
through vasculogenesis33. EPCs possess the surface markers (CD34+ and CD133+) that are 
also found in endothelial cells of growing IHs, suggesting that these bone-marrow-derived 
progenitor cells may play a key role in the pathogenesis of IHs by inducing postnatal formation 
of vascular tissue34,35. In 2008, Khan et al.36 injected immune-deficient mice with CD133+ EPCs, 
which resulted in the development of GLUT-1-positive vascular tumors in these mice. These the 
findings greatly supported angiogenesis theory.
Tissue hypoxia theory
Hypoxia, either local or systemic, seems to be the most influential inducer of IH development. 
Hypoxia stimulates the proliferation of EPCs24,37-41. Transcription factor hypoxia-inducible factor 1a 
(HIF-1a) plays a key role in the tissue hypoxia theory. A hypoxic environment triggers the production 
of HIF-1a. HIF-1a in turn stimulates transcription of target genes, such as GLUT-1, VEGF and IGF-
242-45. These stimulations may take place either directly by HIF-1a signaling or by hypoxia-induced 
regulation of mammalian target of rapamycin (mTOR) complex 1 signaling. Deregulation of the 
mTOR pathway may lead to disorganized growth46,47. Overexpression of VEGF may also take place 
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via the activation of the HIF-2a pathway as a response to the pathologic signal of a “dangerous 
hypoxic situation”48. It has also been demonstrated that the combination of hypoxia and an 
estrogenic environment has a synergic effect on IH endothelial cell proliferation, which may explain 
the greater incidence of IHs in girls48. As stated above, none of these three theories explains the 
pathogenesis of IH completely. Given the great variability of clinical presentations of IH, the uneven 
distribution of IHs over the body, the increased prevalence of IHs in Caucasians, and its familial 
occurrence, it is most likely that IH pathogenesis is not restricted to one factor, but to a combination 
of genetic predisposition and various environmental factors48,49.
1.3 Clinical presentation of infantile hemangioma
IHs develop in the first days, weeks, or months of life. They are not to be confused with congenital 
hemangiomas, which are fully developed at birth and either rapidly involute during the first year of 
life (rapidly involuting congenital hemangiomas) or do not involute at all (non-involuting congenital 
hemangiomas)50,51. Many children who develop an IH are born with a visible precursor lesion, such 
as a pale macule with telangiectasia or mottled vascular stain, at the future IH location52. Fully 
developed, an IH feels elastic and frequently warm. The tumor is not pulsating and is painless, 
except in the case of ulceration48. There is a great variation in size, but in most cases (80%), 
IHs are not greater than 3 cm in diameter8. Recognized risk factors for developing an IH include 
female sex, prematurity, multiple gestation, and low birth weight. Caucasians are at greater risk of 
developing an IH compared with individuals of Hispanic or African origin5,6,53. In the classification 
of the International Society for the Study of Vascular Anomalies (ISSVA), four different patterns 
of IH are described54. According to their pattern, IHs can be grouped into focal, multifocal, 
segmental (plaque-like, covering an embryologic segment), and intermediate/indeterminate48,50. 
Intermediate/indeterminate IHs show characteristics of both focal and segmental IHs. They do not 
entirely encompass an accepted embryologic segment nor do they arise from a single focus48,51. 
Segmental IHs have a higher complication rate and are associated abnormalities55. Apart from the 
pattern, the ISSVA classification makes a distinction between four different types of IHs, according 
to their clinical appearance: (1) superficial (50%-60%); (2) deep (15%); (3) mixed (25%-35%), which 
are distinguished by the layer(s) of the skin affected55; and (4) reticular/abortive/minimal growth, 
which is distinguished by its typical growth pattern56,57.
Superficial IH
Superficial IHs are the most common type of IHs. They involve the papillary dermis and appear 
as bright red “strawberry” lesions in the case of a localized superficial IH (Figure 1) or as a 
plaque-like red lesion in the case of a segmental superficial IH (Figure 2). Segmental IHs are 
more often associated with complications, such as ulceration and associated anomalies, and 
more often require therapy8,48.
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Figure 1. Superficial focal infantile hemangioma
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Figure 2. Superficial segmental infantile hemangioma
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Figure 3. Deep infantile hemangioma
Deep IH
Deep IHs involve the deep, reticular dermis and subcutis, resulting in a tumor with a bluish shine 
or (when deeper) normal skin color (Figure 3). Because of these characteristics, deep IHs may 
easily be misdiagnosed at first55. Deep IHs appear later than superficial IHs; typically around the 
age of 2 mo, and may have a longer proliferative phase compared with the superficial types17,51,52.
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Figure 4. Mixed type infantile hemangioma
Mixed IH
Mixed IHs have both superficial and deep components (Figure 4). The proliferative phase of the 
deep component in mixed IHs also stops later than in superficial IHs17,48.
Reticular/abortive/minimal growth IH
A minority of IHs have arrested or minimal growth beyond the stage resembling the precursor 
lesions. Although their natural course is different from that of the other three types, these lesions 
do express GLUT-1 proteins and have similar other immunohistochemical characteristics (Figure 
5)56,57. Several terms have been used to describe these in the literature. The most commonly used 
terms are reticular, abortive, or minimal growth IH. IHs of this type seem to have a predilection 
for the lower body57. The exact incidence of this type of IH is unknown, but it is believed to be 
relatively rare. However, a recent study by Munden et al.27 in which 578 pregnant women were 
prospectively enrolled and their infants followed up for 9 mo after birth, reports that of the infants 
with an IH, 20% had a reticular, abortive, or minimal growth IH. Despite several hypotheses, the 
pathogenesis of segmental vs focal and superficial vs deep IHs remains unclear19.
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Figure 5. Minimal growth type infantile hemangioma
1.4 Natural history of infantile hemangioma
IHs have a unique pattern of evolution. As stated above, IHs are not fully developed at birth, 
but start to grow shortly after birth (usually within a few days or weeks) from normal appearing 
skin or a precursor lesion51. This typical delay serves as a diagnostic tool, especially in deep 
IHs where the skin color may be bluish or even normal48. After a relatively short proliferative 
phase in the first 3-9 mo of life, the slow involution phase takes place between the median 
age of 2-4 years8,48,58,59. However, the proliferative phase may extend until 12 mo after birth, 
and in some cases, up to 24 mo after birth48,60. Approximately 25%-69% patients with IH may 
develop a residual lesion after complete involution of the IH. Residual lesions may consist of skin 
atrophy, skin surplus, telangiectasias, pigmentation, scarification after ulceration and/or fibrofatty 
tissue3,58,61. Epidermal invasion of an IH in combination with a deep component in the IH is most 
prone to residual lesions58. The difference in reported incidence of residual lesions in several 
studies may be explained by usage of different populations (e.g., secondary/tertiary referral vs 
primary referral).
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1.5 Infantile hemangioma and risk of associated anomalies
There are two types of IHs that may be predictive of an underlying anomaly. These are (1) large, 
flat, segmental IHs of the face, which are associated with PHACE(S) syndrome and (2) IHs in 
the lumbosacral or perineal region, which may be predictive of LUMBAR syndrome [also known 
as Perineal hemangioma, External genitalia malformations, Lipomyelomeningocele, Vesicorenal 
abnormalities, Imperforate anus, and Skin tag (PELVIS) or Spinal dysraphism, Anogenital, 
Cutaneous, Renal and urologic anomalies, associated with an Angioma of Lumbosacral 
localization (SACRAL) syndrome].
PHACE(S) syndrome
The term PHACE was introduced in 1996 by Frieden et al.62, describing a combination of five 
anomalies: (1) posterior fossa abnormalities; (2) hemangioma of the face (segmental); (3) arterial 
abnormalities (intra- and extracranial); (4) cardiac and aortic defects; and (5) eye anomalies. A 
sixth anomaly: Sternal cleft or supraumbilical raphe was added later48. PHACES syndrome is a 
spectrum of anomalies, because most affected children (70%) have only one extracutaneous 
manifestation63. The so-called “Dandy-Walker syndrome” is the most common brain involvement, 
followed by cerebellar hypoplasia or dysgenesia as a result of posterior fossa abnormalities48,63. 
Until 2009, a diagnosis of PHACES syndrome required the presence of a segmental, flat IH of the 
face in addition to one or more of the five anomalies described above62,64. In 2009, a consensus 
was reached defining PHACES as the presence of a characteristic segmental hemangioma or 
hemangioma greater than 5 cm in diameter of the face or scalp plus one major criterion or two 
minor criteria65. The exact incidence of PHACES is unknown. It has been postulated that in 20%-
31% of children with segmental facial IHs, there is an association with PHACES64,66. A full workup 
for PHACES syndrome is suggested in every infant with a large (> 5 cm), segmental, facial 
hemangioma. This includes a complete physical examination as well as careful cardiac (including 
echocardiogram), ophthalmologic and neurologic (including MRI of the head and MRA of the 
entire head and neck area) assessments67.
LUMBAR syndrome
IHs in the lumbosacral area or perineum are also associated with underlying structural 
anomalies. These IHs are also most commonly, but not exclusively, segmental68. A tethered 
cord in the context of spina bifida occulta should be considered, although more extensive 
associated morbidity may be the case. For these conditions, different acronyms have been 
suggested, such as SACRAL69 and PELVIS70. The most recently proposed acronym, LUMBAR is 
preferred; it refers to the association of lower body hemangioma and other cutaneous defects, 
urogenital anomalies, ulceration, myelopathy, bony deformities, anorectal malformations, arterial 
anomalies, and renal anomalies68. There is no diagnostic consensus for LUMBAR, SACRAL, or 
PELVIS, such as for PHACES. Screening with ultrasound scanning of the spine, abdomen, and 
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pelvis is suggested for all patients with a segmental IH greater than 2.5 cm in diameter of any 
lumbosacral or perineal region who are younger than 3 mo. For children older than 3 mo, MRI 
is indicated68,71.
1.6  Management of infantile hemangioma (past, present and future)
The management of IHs has been changed drastically since the discovery of the efficacy of 
propranolol treatment for this indication in 200813. Although there are no uniform international 
guidelines available for the treatment of IHs, propranolol is now considered to be the treatment 
of first choice. Before that, a whole range of treatments had been applied. Some of these 
treatments are rarely or no longer used (e.g., X-irradiation therapy) because of their side effects 
and/or low efficacy.
Past
X-irradiation: Although there was already evidence that IHs involute spontaneously, X-irradiation 
has been widely used for two decades between 1930 and 1950, resulting in (unnecessary) 
radiation exposure and postradiation skin atrophy, pigmentation, telangiectasia, contractures, 
and risk of skin cancer72-74. 
Vincristine: Vincristine is a vinca alkaloid that is widely used in cancer chemotherapy. Treatment 
of IHs with vincristine was first described in 199375. This chemotherapeutic drug inhibits 
microtubule formation, causing arrest of mitosis and subsequent apoptosis76. Additionally, 
vincristine seems to affect angiogenesis77. Nowadays, it may only be indicated for severe IHs 
that are resistant to other therapies. The use of vincristine requires a central venous catheter 
for chronic administration. Furthermore, it has potential severe side effects, such as peripheral 
mixed sensorimotor neurotoxicity78. Other, less severe, side effects include rash, alopecia, and 
local reactions, such as phlebitis and necrosis74. 
Interferon: The use of subcutaneous interferon a-2a and -2b for the treatment of IHs was first 
described in 198979. Its therapeutic effectiveness has been attributed to its anti-angiogenic 
properties. Interferon a induces apoptosis of endothelial cells, which might also explain the 
clinically and histologically observed involution without any sign of inflammation or necrosis80.
Despite its high success rates, the use of interferon in the treatment of complicated IHs has 
been abandoned, because of its major side effects, such as spastic diplegia and blood 
abnormalities81,82.
topical corticosteroids: Potent topical steroids have been described for small, superficial, 
localized IHs83. Side effects include acne, perioral dermatitis, hypertrichosis, cutaneous atrophy, 
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striae, hypopigmentation, and subcutaneous fat atrophy. Since the availability of topical 
b-blockers, with fewer side effects, topical steroids are less often prescribed in current practice76.
topical imiquimod: Imiquimod is an immune modulator. In 2002, the potential of imiquimod to 
shorten the involution phase of IH was first reported84. Due to its anti-angiogenic and apoptotic 
effects, imiquimod contributes to the regression of IH85,86. Its efficacy is equivalent to the efficacy 
of the topical b-blocker timolol (0.5% ophthalmic solution), which was first described a few years 
after the discovery of propranolol treatment for IHs87,88. However, timolol is more effective than 
imiquimod in terms of color involution and onset time89. Furthermore, imiquimod has a less 
favorable adverse reaction profile and has never really become a very common treatment for IHs 
that are suitable for topical therapy88.
Present
Watchful waiting: Knowing IH’s natural history, it is justified to be restrictive in actively treating 
this selflimiting condition. Starting in the 1950s, physicians began to prefer this approach over 
the invasive X-irradiation and/or surgical removal73. At the present time, watchful waiting is still 
considered to be the best approach for the vast majority of patients with IH.
Systemic propranolol (first choice): In 2008, after the report of the very successful therapeutic 
effect of propranolol, IH treatment changed drastically13. Currently, propranolol has become 
the treatment of first choice for IHs. It seems that propranolol stops growth and induces an IH 
regression that is much better and safer than previous therapies90. Recently, Léauté-Labrèze et 
al.91, published a large-scale randomized placebo-controlled trial showing that propranolol is 
effective at a dose of 3 mg/kg per day for 6 mo in the treatment of IHs. This treatment resulted in a 
significantly higher success rate compared with placebo (60% vs 4%). These outcomes are in line 
with the results of the RCT conducted by Hogeling et al.92 in 2011. Earlier, Malik et al.93 had shown 
in their RCT that propranolol had a consistent, rapid therapeutic effect with a lower number of 
complications compared with prednisolone. They also demonstrated that a combination of both 
propranolol and prednisolone was not superior to propranolol alone93. An RCT carried out by 
Zaher et al.94 proved the superiority of oral admission of propranolol compared with topical and 
intralesional application. While the general mechanism of action of propranolol is well established 
as an antagonist of both b1- and b2-adrenergic receptors, the precise mechanism of action on 
IHs remains uncertain19. It is known that propranolol is effective in IH through vasoconstriction, 
inhibition of angiogenesis, induction of apoptosis, or dysregulation of the renin–angiotensin 
system (RAS)95,96. The most common serious adverse effects of propranolol are bradycardia, 
hypoglycemia, and hypotension. Other reported adverse side effects in adults and children 
include bronchospasms, congestive heart failure, hypothermia, somnolence, sleep disturbance, 
nightmares, depression, nausea, vomiting, diarrhea, hyperkalemia, gastro-esophageal reflux, 
psoriatic drug rash, and respiratory symptoms92. Because of the lipophilic nature of propranolol 
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and the potential to penetrate the blood-brain barrier, the probability of affecting the developing 
central nervous system of infants with IH was postulated in a report in 201397. This information 
was further elaborated by Langley et al.18 in 2015. In 2014, Gonski et al.98 showed no gross motor 
development problems in propranolol treated children with IH. This thesis will further shed light 
on this issue 99-101. 
topical b-blockers (first choice): As an alternative to oral b-blockers, topical b-blockers have 
been used for superficial IHs. There are different forms of topical b-blockers, but timolol (0.5% 
ophthalmic solution or 0.1% gel), a non-selective b-blocker, is most widely used76. In 2013, a 
double-blind placebo-controlled RCT was published, comparing topical timolol 0.5% solution 
with placebo for superficial IHs. Timolol was shown to be safe and effective102. Recently, timolol 
0.5% ophthalmic solution was compared with laser treatment, where timolol proved to be a safe, 
effective, and painless alternative to lasers for the treatment of superficial IHs. In mixed IHs, laser 
treatment provided better results than timolol, because of its deeper penetration103. Comparison 
between timolol 0.5% ophthalmic solution and 5% imiquimod cream in 54 patients with IH (half of 
the IH was treated with timolol and other half with imiquimod) showed similar efficacy, but fewer 
side effects were seen in the timolol group89. 
Systemic corticosteroids (second choice): In the 1960s, systemic corticosteroids were 
found to be an effective treatment for IHs104,105. The mechanism of action is still not completely 
understood, but the main theory is that corticosteroids suppress the VEGF-A expression and 
therefore inhibit angiogenesis and/or vasculogenesis106. The usually recommended dose is 2-3 
mg/kg per day, which is most effective in the early proliferating phase107,108. With a treatment 
response of 84%-90% and an overall rebound rate of 36%, this therapy became the first-choice 
therapy for severe IHs, requiring intervention73,107,109. The most common side effects of systemic 
corticosteroids are cushingoid facies (71%), personality changes (29%), gastric irritation (21%), 
fungal infection (6%), and diminished weight gain (42%) and height (35%)110. Other possible side 
effects were systemic infection, hypertension, increased appetite, aseptic necrosis of bones 
and cardiomyopathy20. Currently, systemic corticosteroids have become a little-used second-
line option, because of the lower efficacy and less favorable side-effect profile compared with 
propranolol76. 
Intralesional corticosteroids (in specified indications):
Intralesional corticosteroids (mostly triamcinolone 10 mg/mL) offer an alternative to systemic 
therapy for small IHs76. This therapy was initially used by ophthalmologists for periorbital IHs. 
Because of the risk of retinal artery damage and blindness, intralesional corticosteroids are 
no longer used for periorbital IHs111-113. The common side effects may include subcutaneous 
atrophy and hypopigmentation76.
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Surgery (in specified indications): Surgical treatment of IH is suitable in some specific 
cases. It is indicated in well-circumscribed, pedunculated, or ulcerated lesions that have failed 
to respond to medical treatment, grow rapidly, or cause significant deformity114. Although 
propranolol treatment has been a breakthrough in the management of IHs, many children still 
require plastic surgery after the involution phase. At the present time, most surgical interventions 
in IHs are used to treat those involuted IHs that have left residual lesions, such as skin surplus, 
scarification after ulceration and/or fibrofatty tissue115,116.
Laser therapy (in specified indications): Pulsed dye laser (PDL) is the most commonly used 
laser treatment for superficial and ulcerating IHs and for residual lesions. The literature on the 
effectiveness of PDL in IHs is somewhat controversial. Some earlier studies suggest that early 
treatment of IHs with PDL prevents further growth, induces tumor regression, and improves 
cosmetic outcome, while an randomized controlled trial of 121 infants showed no significant 
difference in complete clearance or minimum residual signs between the PDL-treated group and 
the observational group117-120. Conventional PDL is ineffective in the treatment of deep IHs. Its 
penetration depth is limited due to the optical absorption and scattering in the epidermis and 
dermis121. Introduction of a long-pulse PDL in combination with an epidermal cooling system
made a greater depth of vascular injury possible120,122. Additionally, the use of long-pulse PDL 
with an epidermal cooling system decreases the risk of scarring and induction of ulceration122. 
These types of laser treatment are not painless and may require anesthesia in infants. The larger, 
deep IHs may also be effectively treated using the neodymium-doped yttrium aluminum garnet 
(ND:YAG) laser. However, due to greater risk of scarring or hypo- or hyperpigmentation, this 
therapy should be preserved for difficult, recalcitrant cases121,123,124. Therapy with the fractionated 
CO2 laser is reserved for involuted IHs with residual fibrofatty tissue, atrophic plaques, or other 
textural changes125. 
Future
other systemic b-blockers: Propranolol is a nonselective, lipophilic, b-adrenergic receptor-
antagonist that binds to b1- and b2-adrenergic receptors126. The potential side effects of 
propranolol made physicians and researchers search for an alternative b-blocker that is 
as effective as propranolol, but with fewer side effects. It was suggested that a hydrophilic, 
selective b1- blocker, atenolol, which occurs at lower concentrations in the brain, may have 
these characteristics127,128. A small randomized controlled trial showed no significant difference 
in effectiveness between atenolol and propranolol. However, no difference in adverse effects 
was demonstrated either129. In 2009, oral nadolol, a nonselective b-blocker, which is significantly 
less lipophilic than propranolol, was found to have a significant effect on IH growth, with a 
rapid reduction in size130,131. Recently, a small retrospective study of 48 participants showed 
effects of nadolol similar to those of propranolol. Although serious adverse effects were rare, 
side effects such as sleep disturbance, behavior problems, gastrointestinal symptoms, and cold 
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extremities were still frequently seen132. In 2010, a case report suggested the use of acebutolol 
for the treatment of infantile subglottic hemangioma, because of fewer side effects on resting 
heart rate than propranolol, metoprolol, and atenolol133. In general, b-blocker lipophility and/or 
selectivity are factors that determine the efficacy and side-effect profile. It is unclear whether a 
degree of lipophilicity may be required for tissue penetration and efficacy of IH treatment. It is 
also unclear whether b1- or b2- blockade or a combination of the two is needed to achieve a 
therapeutic effect. In conclusion, the search for a b-blocker with the best effectiveness and the 
most favorable side-effects profile, is still ongoing. 
Rapamycin: Rapamycin, also known as sirolimus, is a bacterial macrolide that also has 
antifungal effects. Since rapamycin is an mTOR inhibitor, it inhibits mTOR signaling, an important 
regulator of growth and proliferation. By inhibiting the mTOR signaling pathway, rapamycin 
decreases the elevated VEGF and HIF-1 levels produced by endothelial cells, and reduces IH 
proliferation134-136. Rapamycin not only negatively affects cell proliferation, but also metabolism, 
as well as angiogenesis. Additionally, rapamycin seems to limit stem cell replicative capabilities, 
affecting vasculogenesis137. At this time, rapamycin treatment use is restricted to clinical trials 
until better safety data are available20,76. 
Angiotensin-converting enzyme inhibitors: With the expanding knowledge on IH 
pathogenesis as a result of the discovery of the efficacy of b-blockers for this indication, the 
regulation of hemogenic endothelium regulated by the RAS in IHs became a point of interest with 
possible therapeutic consequences138. A year later, expression of components of the RAS by 
the endothelium of proliferating IHs was shown139. The role of the RAS in IH is supported by the 
clinical observation of a higher incidence of IHs in premature infants, females, and Caucasians, 
since these groups have a higher renin level or activity than full-term infants, males, and black 
infants, respectively139-142. In connection with these findings, a clinical trial of eight patients with 
IH conducted in 2012 reported promising results for captopril treatment143. Shortly after that, 
it was contradicted by a small retrospective review from Australia, assessing patients with IH 
who had to discontinue treatment with prednisolone because of steroid-induced hypertension. 
Of the patients who received captopril after discontinuing prednisolone, 33% demonstrated no 
changes in IH and 58% demonstrated a worsening144. More prospective randomized studies are 
needed to confirm or disprove these findings. 
oral itraconazole: Recently, efficacy of oral itraconazole was reported in six infants with IH. An 
obvious clinical improvement was noted in all cases during a 3-mo period, with an improvement 
of 80%-100%. Side effects were mild and limited145. The exact mechanism of itraconazole 
effectiveness is not yet fully understood, but it seems that itraconazole has an anti-angiogenic 
effect by inhibiting the VEGRF-2146. The future will teach us what itraconazole adds to the 
therapeutic arsenal for IHs.
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1.7 Assessment of infantile hemangioma severity and activity
The number of prospective studies of IH and its treatment has increased rapidly. Especially since 
the discovery of propranolol for this indication, the need for validated and reliable instruments 
to measure IH severity and activity in clinical trials has become an important issue. In 2011, 
the Hemangioma Activity Score (HAS) was developed, which provided a total activity score by 
measuring the swelling, color, and ulceration of IH. HAS seems to be suitable for valuating IH 
activity and response to treatment over time147,148. In 2012, the Hemangioma Investigator Group 
Research Core developed another scoring system, the Hemangioma Severity Scale (HSS)149. 
The HSS not only takes the objective items, such as size, location, and complications into 
account, but it also assesses the subjective items, such as pain and risk of disfigurement149. 
Recently, a group of Bulgarian dermatologists presented the Hemangioma Activity and Severity 
Index150. Time will tell which scoring system has the best qualities to be implemented in clinical 
practice and used for research purposes.
1.8 Impact of infantile hemangioma on quality of life
It is well known that visible abnormalities, such as IH, may affect the quality of life (QoL) of 
children or their parents/caregivers. Several studies have tried to measure the impact of IH 
on children and their parents. Until recently, either validated non-IH-specific or non-validated 
but IH-specific questionnaires have been used, providing controversial information151-153. This 
controversy may be explained by the absence of attention to impact of IH-specific factors (e.g., 
localization, size, and complications) in non-IH-specific questionnaires or by use of non-validated 
IH-specific questionnaires. Most of them measure the overall psychosocial well-being instead 
of measuring a specific IH-related psychosocial impact151. In addition, others studies have used 
IH-specific questionnaires, but these were non-validated measures. In February 2015, Chamlin 
et al.154 presented a validated IH-specific QoL questionnaire. Our thesis will get further into this 
subject, using a validated IH-specific tool.
1.9 Aims and outlines
IH is the most common benign tumor seen in infancy. Propranolol has become first-line treatment 
for IH with associated morbidity. However, there is no clear consensus about the treatment 
indication for propranolol. Especially in cases where there is no harsh medical treatment 
indication, this may lead to difficult treatment decisions for the physician and parents of the 
patients. Many studies have been published about benefit and adverse effects of the treatment 
with propranolol. We know a lot about the short-term effects, such as bradycardia, hypotension, 
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hypoglycemia and sleep and mood disturbances. However, little is known about long term 
effects of this treatment on the development of young children.
This thesis focuses on three main aims, all with the intention to facilitate the choice of whether or 
not to treat with propranolol. Firstly, to explore the influence of IH on the quality of life of IH-patients 
and their parents (aim 1), secondly, to find a useful tool to determine who should be treated (aim 
2) and finally, to detect possible long-term effects of propranolol treatment of IH (aim 3).
Previously, several studies have tried to measure the impact of IH on children and their parents, 
but results are conflicting, due to the heterogeneity of the questionnaires being used (most 
of them being not IH-specific) and due to the differences between the included participants. 
Chapter 2 uses a Dutch version of a validated IH-specific quality of life questionnaire (IH-QoL)154 
to investigate the impact of IH on quality of life in young children and to detect the possible 
correlation between IH-severity and IH-activity. Accurate assessment of impact of IH on the quality 
of life of the patient and their parents gives direction to the choice of whether or not to treat.
Since the IH is a self limiting disease, in most of the cases no treatment is required. Currently, 
IH-severity and the need for treatment are assessed subjectively by the attending physician in 
dialogue with the parents. Chapter 3 evaluates the ability of the Hemangioma Severity Scale to 
quantify the severity of IH and its ability to predict the need for treatment with propranolol. Tools 
like this empower physicians and parents on the timely and right indication for treatment so that 
delay and under-treatment, but also over-treatment, can be prevented.
With regard to our third aim, we performed three studies looking into the (long term) effects of 
propranolol treatment on the development of the children (chapter 4). Chapter 4.1 evaluates 
whether propranolol treatment affects the psychomotor development of infants at age of 3 years, 
using the data from the Dutch Well Child Preventive Health Care Clinics. In chapter 4.2 we 
compared the growth and development in 4 years old children treated with propranolol for IH 
with non-treated healthy controls, using the 48-months Ages and Stages Questionnaire. Finally, 
chapter 4.3 assesses psychological (social, emotional, behavioral, and executive) functioning 
in 7 years old children treated with propranolol for IH. The older the patients, the more advanced 
tests can be performed. In this chapter the Behavior Rating Inventory of Executive Function, Social 
Emotional Questionnaire, Child Behavior Checklist, and Strengths and Difficulties Questionnaire 
were used. With the determination of any long-term effects of treatment, the choice of whether or 
not to treat can be made with more baggage (and in case of no long-term effect with more trust).
In chapter 5 the results presented in this thesis are summarized and discussed.
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Quality of life (QoL) data are lacking in children with infantile hemangioma (IH) and their parents/
caregivers. Available data are conflicting.  
objectives
To determine QoL of (parents of) patients with IH in the proliferative phase related to IH-severity 
and activity. 
Methods
Parents of 59 IH-patients (≤ 6 months) were asked to fill in the Dutch IH-specific QoL-questionnaire 
(D-IH-QoL) within one month after their first visit to our tertiary referral center. Hemangioma 
Severity Scale (HSS) score and Hemangioma Activity Score (HAS) were assessed.
 
Results
D-IH-QoL-scores were low; mean: 22.6 (range 1-56; max 116). Mean HSS-score and HAS-score 
were 8.4 (range 2-28) and 4.0 (range 1.5-6) respectively. Higher HSS-scores correlated with 
worse QoL (ρ = 0.358; P = 0.005). HAS-scores did not correlate with QoL-scores.
Conclusion
An IH only seems to have limited influence on QoL in young children and their parents in the first 
month of their first doctor’s visit. QoL is more affected in more severe IH. Physicians should be 
alert to the impact of IH, optionally guided by the HSS-score.  




Skin conditions in children, such as infantile hemangioma (IH), the most common benign 
vascular tumor of infancy 1, 2, may be associated with an impaired quality of life (QoL) of the 
children and/or their parents/caregivers 3, 4. Several studies have tried to measure the impact of 
IH on children and their parents, but results are conflicting 5-9. Only one of these studies used a 
validated IH-specific Hemangioma Family Burden (HFB) questionnaire, concluding that burden 
of disease of IH may be underestimated by physicians and that parents of children with severe 
IH experience a high burden 9. Questionnaires used in other studies were either not validated or 
not IH-specific. In most studies, the overall psychosocial wellbeing is assessed instead of IH-
specific psychosocial factors (e.g. location, size, complications).
 
In the present study, we used a Dutch version (D-IH-QoL) of a validated IH-specific QoL 
questionnaire (IH-QoL) to focus on the impact of IH on QoL (and not the impact of other features, 
which can be the case when using the not IH-specific tools) in young children with an IH in the 
growth phase, at which impact and the parents’ worries are maximal. The correlation between 
IH-related QoL and the hemangioma severity scale (HSS) score and the Hemangioma Activity 
Score (HAS) was assessed. 
MethoDS
D-Ih-QoL
The original English IH-QoL 10 measures the QoL of young children. It was developed using a 
cohort of 220 IH-children with a mean age of 6.5 months (range 0.5-19 months). It consists of 
29 items/questions divided into four scales 1. child physical symptoms (CPS), 2. child social 
interactions (CSI), 3. parent emotional functioning (PEF) and 4. parent psychosocial functioning 
(PPF). For each of the 29 items/questions, 0-4 points can be obtained (0: never; 1: rarely; 2: 
sometimes; 3: often; 4: all the day). The IH-QoL can be reported as a total score (0-116) or as a 
score for each scale separately. Each scale can be used and interpreted separately. The higher 
the score the more impact of IH on QoL 10. 
The translation of IH-QoL into Dutch (D-IH-QoL) was performed following the procedure proposed 
by Guillemin et al. 11. Efforts were made to keep the exact meaning of the original items. 
hSS and hAS
The HSS measures the overall severity of an IH, using both objective items (size, location and 
complications) and subjective items (pain). Also, the risks for associated structural anomalies 
and disfigurement are included. The higher the score, the more severe the IH 12. 
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The HAS measures the proliferative activity of an IH, using only objective items (swelling, color 
and ulceration). The higher the score the more active the IH 13. Both scales are validated.
Patients and procedure
Between June 2015 and July 2016 the parents of all referred patients (≤ 6 months of age) who 
visited our out-patient department for the first time with an IH in the active phase were asked to 
participate in this study (n = 124), assuming that the impact on the well being of the parents 
and their child would be maximized in this phase. Both parents provided informed consent to 
participate in the study. Data on gestational age, birth weight, sex, socioeconomic status (SES) 
(based on highest education of the mother) and location of the IH were collected (Table 1). 
The HSS- and HAS-scoring were assessed using the photographs taken during the first visit 
to our center 12, 13. 
To assess impact of IH on the family, parents were asked to fill in the D-IH-QoL questionnaire 
within one month after their first visit to our center and before any intervention for the IH 10. 
table 1. Characteristics of children with infantile haemangioma (IH)
 Variable Ih-children (n = 59)
Female gender 45 (76.3%)
Mean gestational age in weeks (25th-75th percentile) 38.5 (37-40)
Mean birthweight in grams (range) 3229 (1155-4480)
Mean age in monthsa (range) 4.4 (2-6)
Education of mother b 
Low 
Low to intermediate 







a Age at the moment of assessment
b  Low: primary school or less; low to intermediate: low-level technical and vocational training (<12 years 
of education); intermediate to high: high school or medium-level technical and vocational training (12-16 
years of education); high: university or high-level technical and vocational training (>16 years of education)




The primary outcomes were the D-IH-QoL scores, the HSS-scores and the HAS-scores. The 
D-IH-QoL scores were reported as the mean score for each scale separately (CPS; CSI; PEF; 
PPF) and as the mean total score with a range. The HSS-scores and the HAS-scores were 
also reported as the mean score with a range. To examine the possible correlation between the 
D-IH-QoL scores (total score and each scale separately) and the HSS-scores and HAS-scores, 
Spearman rank correlation coefficient (r) (or Pearson’s correlation coefficient in case of normal 
distribution) was calculated. We also calculated the Spearman rank correlation coefficient (or 
Pearson’s correlation coefficient) to examine the possible relation between the D-IH-QoL scores 
and the SES and age. Differences in D-IH-QoL mean scores of patients with IH in facial area 
were compared with the mean scores of patients with IH in non-facial area using the independent 
T-test. Correlation coefficients and T-tests were considered statistically significant at P < 0.05. 
ReSuLtS
The parents of 59 (47.6%) of the 124 eligible patients were willing to participate in the study and 
signed informed consent (Fig. 1). The majority of the questionnaires were filled in by the mother 
(93,2). Other 6,7% were filled in by the father. Mean age at the start of the data-assessment was 
4.4 months (range 2-6). Forty patients (67.8%) had an IH in the facial area. The mean scores and 
ranges of D-IH-QoL and each scale separately are listed in Table 2. The mean HSS-score and 
HAS-score were 8.4 (range 2-28; median 9.0) and 4.0 (range 1.5-6; median 4.0) respectively. 
The D-IH-QoL total scores correlated positively with the HSS-scores (ρ = 0.358; P = 0.005) (Fig. 
2). Also the PEF-scores, PPF-scores and CPS-scores correlated positively with the HSS-scores 
(ρ = 0.302; P = 0.020) (ρ = 0.299; P = 0.022) (ρ = 0.349; P = 0.007). The HAS-scores did not 
correlate with any of the QoL-scores. Also age and SES did not correlate with any of the QoL-
scores. Children with IH in the facial area had significant higher mean D-IH-QoL total score and 
PPF-score than children with IH in other locations: respectively mean total score of 25.3 versus 
17.1 (P = 0.027) and mean PPF-score of 4.38 versus 1.94 (P = 0.021). 
table 2.  Mean scores and ranges of the Dutch version of an infantile hemangioma specific Quality of Life 
questionnaire (D-IH-QoL) in 59 children 
 D-Ih-QoL scale Mean score (range) [max]
Total score 22.6 (1-56) [116]
Child physical symptoms scale (CPS) 1.4 (0-9) [16]
Child social interactions scale (CSI) 4.9 (0-12) [20]
Parent emotional functioning scale (PEF) 12.9 (0-27) [40]


















































Figure 1. Sampling procedure. IH, infantile hemangioma.
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Figure 2.  Correlation between the Hemangioma Severity Scale (HSS) scores and the total scores in a Dutch 
version of IH-specific QoL questionnaire (D-IH-QoL).
DISCuSSIoN 
Regarding our main aim, the QoL of IH-patients and their parents only seemed to be affected 
mildly. In the majority of the questions of the D-IH-QoL parents filled in ‘never’ as the answer 
(67.4%). QoL was negatively correlated with IH severity (HSS) as well as visible location (face). 
We found no correlation between the IH activity, as determined by the HAS-score, and the QoL. 
This finding may be explained by the fact that quality-of-life-defining issues such as IH- location 
and pain are not incorporated in the HAS. These findings show the importance of these items 
for the parents. Finally, SES and age of the infant did not correlate with any of the QoL-scores. 
The relatively low D-IH-QoL-scores, despite serious IH in a tertiary referral center, may be 
explained by the fact that parents are already (partially) reassured during the first consultation 
in our tertiary referral center. It would be interesting to take the questionnaire and HSS-scores 
before consulting a specialized doctor. Secondly, the IH-QoL combines emotional/ psychosocial 
and physical experience, and most IH do not cause pain or systemic illness, which may also be 
the reason why the impact on the QoL is relatively low. Thirdly, since the mean age of our cohort 
was 4.4 months and the most rapid growth of an IH commonly ends by the age of 4 months, 
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this may also be the reason for the mild impact on the QoL. A final possible explanation is the 
relatively low mean HSS-score (8,4). Further studies with a greater amount of participants may 
result in greater mean HSS-scores and higher D-IH-QoL scores.
A strength of our study is the fact that it is the first study of its kind where the IH-specific QoL score is 
being used in relation to the hemangioma severity and activity. The data were gathered from young 
children with an IH who were not treated, assessing not only the overall psychosocial wellbeing, 
but specific IH-related psychosocial impact of IH specific factors (e.g. location, size, complications). 
Limitations were the relatively small cohort, the limited participation of the eligible patients, absence of 
the reference-values for disease-specific QoL in IH and mothers primarily filling in the questionnaire.
CoNCLuSIoN 
Our study showed that the impact of an IH on patients and their parents is relatively mild at the 
age of 4.4 months. Secondly, we established that the HSS-score could be a proxy for the impact 
of IH on the QoL, in which the facial location of an IH seems to play an important role in parent 
perception. The HAS-score seems to lack this ability. We suggest the use of HSS and/or IH-QoL, 
in daily practice. Both tests are easy to use and to calculate. Professionals should be aware of the 
possible psychological impact of IH on the patients and their parents, especially in the cases with 
high HSS-scores and IH in the facial areas. Therefore we encourage the primary care providers to 
refer their patients to a specialist earlier. We are curious about the effect of IH-treatment on the QoL. 
ABBReVIAtIoNS
IH - Infantile hemangioma; 
QoL - Quality of Life;
D-IH-QoL - Dutch IH-specific QoL-questionnaire;
HSS - Hemangioma Severity Scale;
HAS - Hemangioma Activity Score;
CPS - child physical symptoms;
CSI - child social interactions;
PEF -  parent emotional functioning;
PPF - parent psychosocial functioning; 
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‘to treat or not to treat’

3.1
Use of the Hemangioma Severity Scale 





C.J.M. van der Vleuten





The Hemangioma Severity Scale (HSS) assesses the severity of an infantile hemangioma (IH).
objective
First, to compare HSS scores between patients with IH for whom propranolol treatment was 
indicated at their first visit and those who were not treated. Second, to assess suitable cutoff 
values for the need for propranolol treatment.
Method
All patients with IH who attended our tertiary referral center since 2008 and were 0 to 6 months 
of age at their first visit were included. They were divided into propranolol and no-propranolol 
groups on the basis of choice of treatment at their first visit. HSS scores were assessed, and 
median scores were compared.
Results
A total of 657 children (342 in the propranolol group) were included. The median HSS score (25th-
75th percentile) in the propranolol group was 10 (range, 8-14) compared with 7 (range, 4-9) in 
the no-propranolol group (P < .001). Cutoff values of 6 or lower (no indication for treatment) and 
11 or higher (indication for treatment) resulted in 94% sensitivity and 89% specificity, respectively.
Limitations
HSS scoring was not completely blinded.
Conclusion
The HSS with cutoff values of 6 or lower and 11 or higher could be used as a triage tool for 
propranolol treatment. Patient age, IH type, and parental preference may also contribute to 
treatment decisions.
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INtRoDuCtIoN
Discovery of the benefit of propranolol in 20081 revolutionized the treatment of infantile 
hemangiomas (IHs).2 IH is a benign self-limiting tumor, and most do not require treatment.3 
Propranolol is indicated for more severe IH.
Currently, IH severity and the need for treatment are assessed subjectively by the attending 
physician in dialogue with the parents. To quantify severity, several scoring tools have been 
developed; of these, the Hemangioma Severity Scale (HSS) seems the most promising.4-6
Studies on correlation between scoring systems and treatment indication are limited.5,7 The main 
objective of our study was to assess IH severity by using the HSS at the first consultation, when 
treatment was determined. Our secondary objective was to find suitable HSS cutoff values for 
propranolol treatment. A tertiary objective was to determine factors influencing the choice of 
treatment that are not directly covered in the HSS.
MethoDS
Data from patients with IH at first consultation (from September 2008 to November 2016) at our 
tertiary referral center were collected retrospectively. All infants between 0 and 6 months of age 
were included, as propranolol treatment is preferably started before the age of 6 months. The 
first consultation was with a pediatrician, pediatric surgeon, ophthalmologist, or dermatologist. 
Patients were excluded if no photographs were taken before initiation of treatment or when no 
documented history was available; infants treated with β-blockers before the first consultation 
were also excluded. Fig 1 provides an overview of the sampling procedure. HSS scores were 
assessed by two clinicians (B.H. and C.vd V.) by using photographs and data from the medical 
records.
Patients were divided into two groups, propranolol and no-propranolol, depending on the course 
of treatment decided by the attending physician at the first visit. Patients whose treatment regimen 
was changed during follow-up (eg, from topical timolol to oral propranolol) were assessed in the 
group to which they were primarily appointed, and only the HSS score from their first visit was 
used. In patients with multiple IHs, the IH with the highest HSS score was used, as were the 
characteristics of that specific lesion. IHs were specified on the basis of pattern (focal, multifocal, 
segmental, or indeterminate) and type (superficial, deep, mixed, reticular/abortive growth, or 
others).8 Single IHs were described as focal or segmental; multiple IHs were described as 
multifocal, even when the assessed IH was segmental.
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The resulting HSS scores were checked for normal distribution and compared by using the 
Mann-Whitney U test. Baseline characteristics and the separate clinical features of the HSS 
were compared by using Fisher’s exact test (parametric data) or the Mann-Whitney U test 
(nonparametric data). P values less than .05 were considered significant. Ultimately, a receiver 
operating characteristic analysis was done to determine the strength of the HSS and find suitable 
cutoff values for possible indication of propranolol treatment. The study was approved by the 
local medical ethics committee. All analyses were done with SPSS software (version 22.0, IBM 
Corp, Armonk, NY).
ReSuLtS
A total of 657 patients were included in our study (Table I). Patients in the propranolol group 
(n = 342) were younger at first visit (P = .001) and had a deep IH component more often than in 
the no-propranolol group (P < .001).
During follow up, 58 of 315 children in the no-propranolol group (18%) switched to propranolol 
(switchers group), with a median (25th-75th percentile) of 34 days (range, 20-50) until indication 
for propranolol was determined. The median age at which propranolol was initiated was 118 days 
(range, 86-161). The primary indications for propranolol treatment are listed in Table II. The 
reasons for starting propranolol were different in both groups: in the propranolol group, the main 
indications were function-threatening IHs, ulceration, and risk for scarring or disfigurement. In 
the switchers group, the indications were mainly rapid growth and ulceration of the IH. In this 
group, parental preference for treatment was a more important factor.
The results of the separate clinical features of the HSS in both groups are listed in Table III. The 
median HSS score (25th-75th percentile) in the propranolol group was higher: 10 (range, 8-14) 
than the 7 (range, 4-9) in the no-propranolol group (P < .001). In the switchers group, median 
HSS score at first visit was 8 (range, 5-9).
Given that the HSS scores were significantly different in the propranolol versus no-propranolol 
groups, a receiver operating characteristic analysis was performed; it resulted in an area under 
the curve (AUC) of 0.811 (95% confidence interval, 0.778-0.844). In light of the distribution of 
HSS scores in the propranolol and no-propranolol groups, as seen in Fig 2, cutoff values of 11 
for propranolol treatment and 6 for no propranolol treatment were chosen. This resulted in a 
specificity of 89% (HSS ≥ 11) and sensitivity of 94% (HSS ≤ 6).
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DISCuSSIoN
IHs are heterogeneous and their severity or activity is not easy to quantify. The HSS is user-friendly 
and comprehensive compared with other available scoring tools, such as the Hemangioma 
Activity Score or Hemangioma Activity and Severity Index.4,5 In this study, using HSS scores of 
11 or higher as a marker for propranolol treatment and HSS scores of 6 or lower as a marker for 
watchful waiting or topical β-blocker treatment only resulted in achievement of solid specificity 
and sensitivity values.
The difference in HSS scores between the propranolol and no-propranolol groups is illustrated 
by the difference in the separate clinical features of HSS.
The AUC of 0.811 suggests that the HSS is an adequate test to determine the need to start 
treatment with propranolol, as a test with an AUC between 0.8 and 0.9 is potentially useful. HSS 
scores higher than 6 and lower than 11 cannot differentiate enough to determine treatment 
indication. Other possible cutoff values could be 7 and 10. These values, however, resulted in a 
lower sensitivity of 88% (HSS ≤ 7) and specificity of 84% (HSS ≥ 10) and are therefore less solid 
markers for treatment indication.
Other important factors, such as age at first visit and IH type, are not incorporated into the HSS 
but could influence propranolol treatment indication.
The children in the propranolol group were substantially (10 days) younger at their first visit than 
those in the no-propranolol group (P = .001). Our hypothesis is that fast-growing IHs cause 
functional problems or disfigurement (with higher HSS scores) at an earlier age and demand 
quicker referral to the treating physician. We found a significant difference in IH type,8 with more 
IHs with a deep component in the propranolol group than in the no-propranolol group. Even 
though IH type is not explicitly mentioned in the HSS, it indirectly contributes to the risk/likelihood 
of disfigurement and complications with residual lesions9 and therefore may influence treatment 
indication.
There are limitations to using the HSS as a directive for treatment indication. The clinical feature 
risk for associated anomalies assigns extra points to IHs at higher risk for PHACE syndrome 
(posterior fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/coarctation of 
the aorta, and eye anomalies) syndrome and LUMBAR syndrome (lower body hemangioma 
and other cutaneous defects, urogenital anomalies, ulceration, myelopathy, bony deformities, 
anorectal anomalies, arterial anomalies, and renal anomalies).10,11 The extra points indicate the 
chance of underlying anomalies, but not the severity of the IH itself. So even though most IHs 
associated with PHACE or LUMBAR have high HSS scores, they do not necessarily require 
treatment with propranolol. Additionally, the risk/likelihood of disfigurement is not always easy 
to predict, even for physicians with experience in the field. This may result in a greater range of 
HSS scores, with overlapping of propranolol and no-propranolol HSS scores between 6 and 11 
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(Fig 1). We suggest the creation of a new triage tool with elements from the HSS and inclusion 
of factors that directly affect the choice of treatment, such as age of the patient, IH-type, and 
parental preferences.
There is 1 study7 whose authors sought to use the HSS as a triage tool for treatment of IH. 
Because of a relatively small sample size (N = 106), they were not able to perform a subgroup 
analysis. Patients treated with different treatment modalities, such as timolol, laser therapy, 
and systemic drugs (including propranolol), were included in 1 single “treated group.” Also, 
patients who received more than 1 treatment were also included in the treated group. Despite 
this limitation, Mull et al. concluded that IHs with HSS scores lower than 6 have a low likelihood 
ratio of receiving any treatment. IHs with HSS scores higher than 10 were labeled as those 
with great likelihood of receiving local or systemic therapy. These cutoff values are close to our 
findings. Another study5 tried to link a scoring tool, the Hemangioma Activity and Severity Index, 
to treatment decisions. This study lacked evidence to substantiate the link between scoring and 
treatment indication and is therefore less useful in practice. The Hemangioma Activity Score4 is 
particularly suited for longitudinal use.12 but whether it can be used to direct treatment decisions 
is unclear.
A strength of our study is the large group of patients from a single center. A limitation is that we 
were unable to score photographs completely blinded. Many of the infants were known to us and 
we knew whether they had received propranolol. Additionally, the risk/likelihood of disfigurement 
was potentially inaccurate.
By using the HSS score as a triage tool, less experienced physicians may be able to decide 
whether a child with IH should be referred for propranolol treatment. Children with an HSS score 
of 11 or higher should be treated (and/or referred to an expertise center). For children with a HSS 
score of 6 or lower, there is usually no indication for propranolol treatment. Factors such as age 
of the child at first consultation and IH type, in addition to the not insignificant role of parental 
preference, might help in guiding treatment indication in children with a HSS score higher than 6 
and lower than 11. Prospective studies utilizing these cutoff scores would be of value.
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table I. Characteristics of children with IH in the propranolol-treated and no-propranolol groups















Median age in days (25th-75th percentile) 90 (61-113) 100 (69-129) .001








Mean birth weight (range) in grams3  3234 (1844-4624) 3214 (1671-4757) ns









































IH, Infantile hemangioma; ns, not significant.
1 P values are based on Mann-Whitney U test for nonparametric data and Fisher’s exact test for parametric 
data. 
2 Based on 616 cases (93.8%); 41 cases (6,2%) are missing. 
3 Based on 514 cases (78.2%); 143 cases (21.8%) are missing. 
table II. Primary treatment indication for oral propranolol in the propranolol group and patients in the no-
propranolol group who switched treatment to oral propranolol during the follow up period
Primary treatment indication total patients  
(n = 400)
Propranolol at first visit  
(n = 342)
Switchers group  
(n = 58)
(Possibly) function-threatening 164 (48.0%) 0 (0.0%)
Ulceration 69 (20.2%) 17 (29.3%)
Cosmetic 66 (19.3%) 0 (0.0%)
Prevention of ulceration 21 (6.1%) 1 (1.7%)
Choice of parents 11 (3.2%) 9 (15.5%)
(Fast) growth 9 (2.6%) 30 (51.7%)
Other 2 (0.6%) 1 (1.7%)
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table III. Results for the separate clinical features of the HSS in the propranolol and no-propranolol groups











































































Risk for associated 
structural anomalies
None
Facial and ≥ 5cm in longest 
dimension
≥2.5cm and overlying midline 
lumbosacral spine




































































Risk of disfigurement None
Minimal skin textural change and 
or telangiectasia
Redundant fibrofatty tissue, 
alopecia or scar without 
distortion of anatomic landmarks














Median HSS score 10 7 <.001
HSS, Hemangioma Severity Scale; ns, not significant.
1 P-values are based on Fisher’s exact test for parametric data and Mann Whitney U test for non parametric data.
2 Numbers exceed 342 (and 100%), as there were patients with multiple complications
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Fig 1. li  procedur  for study evaluating the Hemangioma Severity Scale score as a tool for 
propranolol treatment i dication. IH, infantile hemangioma.
Fig 2. Distribution of the Hemangioma Severity Scale (HSS) score in the propranolol and no-propranolol 




Fig 2. Distribution of the Hemangioma Severity Scale (HSS) score in the propranolol and no-propranolol 
group of infants with infantile hemangioma.
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To the Editor: Propranolol treatment for infantile hemangioma (IH) has been increasing since 
2008. Concerns about possible negative effects of this lipophilic drug with respect to the central 
nervous system were raised in a recent article by Langley and Pope.1 Treatment with propranolol 
was initiated in 272 patients with IH at our tertiary referral center between September 2008 and 
May 2013. To assess the psychomotor development of infants with IH treated with propranolol, 
we collected and interpreted information from the Dutch Well Child Preventive Health Care 
Clinics (WCPHCC), using the Van Wiechen scheme (VWS). The VWS is a Dutch screening 
instrument based on the developmental model of the American developmental psychologist 
and pediatrician Arnold Gesell.2,3
Of the original cohort, 184 patients met our inclusion criteria. Patients with other risk factors for 
developmental delay were excluded, which resulted in 141 eligible patients. Informed consent 
was obtained from 104 (73.8%) parents. The WCPHCC could provide us with information on 103 
patients (Fig 1). In the case of twins (n = 5), data about the twin not treated with propranolol 
were evaluated for paired comparison. The VWS consists of 3 sections assessing fine motor/
adaptation/personal social functioning, communication, and gross motor skills, with each 
involving a number of tasks that vary with age. The VWS integrates developmental milestones in 
such a way that 90% of the normal Dutch population (prematurely born children excluded) can 
perform specific tasks at a specific age. When a child performs the task well, a positive (plus) 
score is given; when a child fails, a negative (minus) score is given. A minus score indicates an 
increased risk for psychomotor developmental delay specific for the task in the section. There 
are no distinct cutoff points that define developmental delay. Before the study, we defined 3 
or more minus scores in any 1 particular section as a deviant section. This is regarded as an 
abnormal VWS outcome, predicts an increased risk for developmental delay, and is an indication 
for referral to a pediatrician. The latest available assessment points (78.6% obtained between 2 
and 4 years of age) were used. Only 1 child (1%) (95% CI: 0.03%; 5.29%) scored 3 minus scores 
in 1 section (communication) on the VWS and was therefore labeled as having an increased risk 
for psychomotor developmental delay (Fig 2). This was a 3-year-old child of immigrant parents. 
Cultural aspects and a language barrier may have accounted for his delayed communication 
skills. No child was referred to a pediatrician for further evaluation of possible psychomotor 
delay at any stage. None of the 5 propranolol-treated twins scored 3 or more minus scores in 
1 particular section, in contrast to the untreated twin sibling group in which 1 child scored 3 or 
more minus scores.
In conclusion, our study did not detect evidence of psychomotor developmental delay among 
infants with IH treated with propranolol. It remains possible that propranolol treatment causes 
subtle adverse effects, which cannot be traced with tools such as the VWS. Future prospective 
studies using universal screening tools such as the Parents Evaluation of Developmental Status 
(PEDS), the Ages and Stages Questionnaire (ASQ),4,5 or more advanced neuropsychologic tests 
are needed to support our findings.
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Age <18 months [n=73]
Gestation period of ≤ 35 weeks [n=22]
Propranolol use < 6 months [n=15]
Birth weight of ≤ P10 [n=10]
Complicated neonatal phase [n=3]
Relevant comorbidity [n=5]
Use of relevant medication [n=2]
Psychomotor development delay before propranolol use [n=1]
2. Eligible, not recruited [n=38]
Could not be traced (moved/treatment elsewhere/no answer [n=34]
WCPHCC could not provide VWS [n=1]
Refused to participate [n=3]
Fig 1. Sampling procedure. IH, infantile hemangioma; WCPHCC, Well Child Preventive Health
Care Clinic; VWS, Van Wiechen scheme.
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Fig 2. Number of patients with minus scores in 1 single VWS section. VWS, Van Wiechen-scheme, a 
Dutch screening instrument used by the Well Child Preventive Health Care Clinics (WCPHCC) to assess 
the psychomotor development of children between the age of 1 month and 4.5 years. A minus score 
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Long-term adverse effects of propranolol treatment for infantile hemangioma (IH) in young 
children have been suggested.
objective
To compare growth and development in children treated with propranolol for IH with
nontreated healthy controls.
Methods
Eighty two (73%) children with IH aged 43 to 51 months treated with propranolol for 6 months or 
longer, and without other developmental risk factors, were recruited (cases) and matched with 
4 twin counterparts and 78 children from a community-based cohort (control subjects). Parents 
completed the 48-months Ages and Stages Questionnaire (ASQ). Percentages of children with 
abnormal ASQ results were compared using χ2 analyses. Mean ASQ scores and growth were 
compared using Mann-Whitney U tests.
Results
Six (7.3%) cases had abnormal ASQ results, compared with 10 (12.2%) controls (P = .292). 
Mean ASQ total score (25th-75th percentile) was 52.9 (50.8-57.0) for cases and 51.9 (49.0-56.0) 
for controls (P = .383). Height and weight of cases and controls were comparable.
Limitations
A parent-completed screening instrument was used. The exclusion of children born at
gestational age less than 36 weeks and/or children born small for gestational age partly limits 
generalizability.
Conclusion
We found no increased developmental risk or growth impairment at age 4 years in patients with 
IH treated with propranolol. 
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INtRoDuCtIoN
Propranolol is considered to be first-line treatment for infantile hemangiomas (IH) with substantial 
associated morbidity. Many studies have been published about benefit and adverse effects.1-5 
Short-term side effects, such as relative bradycardia, hypotension, and hypoglycemia
are usually mild, self-limiting, or easy to manage. Sleep and mood disturbances are frequently 
reported by parents and are less easy to quantify and treat.6,7 
Little is known about long-term effects of treatment on the development of young children. Two 
reports have suggested that propranolol could affect the central nervous system of infants, 
because of its lipophilic nature and ability to penetrate the bloodbrain barrier. Impairment in 
forming emotional arousing memories has been found in studies of propranolol in animals and 
in adult volunteers.8,9 Long-term suboptimal sleep has been linked to measurable effects on 
both the brain and behavior, especially in young children.10-13 In a preliminary retrospective pilot 
study, our group found no negative effect of propranolol treatment (n = 103) on psychomotor 
development in toddlers (median age 24 months, range 15-48 months).14 No studies concerning 
influence of propranolol treatment on growth have been published to our knowledge, although 
beta-blockers are known to impair fetal growth.15-18
Our objective was to compare development in patients with IH treated with propranolol versus that 
of healthy children not treated with propranolol at age 4 years. Our second aim was to compare 
developmental outcome for age at start of propranolol treatment and treatment duration. Our 
third aim was to compare growth between treated and nontreated children at age 4 years. We 
examined frequency of mood and sleep disturbances as a result of propranolol treatment and 
their relation to developmental outcome.
MethoDS
Patients
Between August 2013 and May 2015 the parents of 111 patients with IH, born in 2009 through 
2011, were asked to participate in this prospective study. The inclusion criteria were propranolol 
treatment 6 months or longer and age between 43 and 51 months at the time of assessment. 
Children with other known risk factors for developmental delay or growth restriction, such as 
prematurity (here defined as <36 weeks of gestation), small for gestational age (birthweight 
≤P10 for gestational age on Dutch growth charts), or other major congenital malformations, were 
excluded, as were children with relevant co-medication use. Two patients whose parents declined 
to participate in an earlier study14 were also excluded. Children with developmental (Ages and 
Stages Questionnaire [ASQ]) and growth data from a prospective community-based cohort 
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(Longitudinal Preterm Outcome Project [LOLLIPOP]) of Dutch children born in 2002 through 
2004 were matched retrospectively as control subjects.19 Children were matched for gestational 
age, gender, birthweight, age of completing the ASQ, and highest completed educational level 
of the mother. In the case of twins (n = 4), data from the nontreated twin sibling were added as 
a matched control. Fig 1 provides an overview of the sampling procedure. 
The study was approved by the local institutional medical ethical review board. Data from the 
LOLLIPOP study were used in a de-identified design for this study. Written informed consent was 
obtained from both parents. 
MethoDS
Data on gestational age, gender, birthweight, and ethnicity were collected from medical charts. 
Data on educational level of the mother and mood and sleep disturbance during and after 
propranolol-treatment were collected by parental questionnaire (Appendix 1). Parents were asked 
to complete the Dutch 48-months ASQ version. The ASQ consists of 5 sections: communication, 
fine motor, gross motor, problem solving, and personal social functioning. Each section contains 
6 questions on developmental milestones. Parents can answer ‘‘yes,’’ ‘‘sometimes,’’ or ‘‘not yet’’ 
with a score of 10, 5, or 0 points, respectively.20 Domain scores are added up and divided by 5 
to compute an ASQ total score. According to the manual, domain scores less than -2SD below 
the mean were considered abnormal, and a child with 1 or more abnormal domain scores was 
considered to have an abnormal ASQ result, indicating possible developmental delay. 
Data on height and weight of propranolol-treated children were retrospectively collected from 
charts completed during the routine scheduled last visit to their local Preventive Child Health 
Care clinic at the age of 45 (range: 43-49) months. These data were matched to data collected 
in the same way for the control children within the LOLLIPOP cohort.21 
Data analysis 
We compared the background characteristics of the propranolol-treated group and matched 
control group (Table I). We compared rates of children with abnormal ASQ results (abnormal 
score for ≥1 domain) with χ2 analyses. We compared mean ASQ domain and ASQ total scores. 
Data were checked for normal distribution. Differences in mean scores were tested using 
the unpaired t test (or Mann-Whitney U test in case of nonparametric data). Spearman rank 
correlation coefficient was calculated to determine the correlation between the age at the start 
and the duration of propranolol treatment on the one hand and abnormal ASQ results (≥1 
deviant ASQ domain score) and the ASQ total score on the other. Mean growth data (height and 
weight) were compared with Mann-Whitney U tests. Data on mood and sleep disturbance were 
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compared with abnormal ASQ results using the χ2 analyses. Tests were considered statistically 
significant at P less than .05. All analyses were done using software (SPSS, Version 22.0, IBM 
Corp, Armonk, NY).
ReSuLtS
In total 82 (72.6%) of 113 eligible patients were recruited for the study (Table I). Treatment 
indications are listed in Table II. Propranolol treatment was started on average at 4.8 months of
age (range 1.0-16.0 months; SD 2.8). The dose was adjusted to a target dosage of 2 to 3 mg/
kg daily, guided by body weight until the age of 9 months, after which the dose was no longer 
increased. Mean duration of treatment was 12.9 months (range 6.1-27.3 months). Cases and 
controls did not differ on any of the main characteristics (P > .05) (Table I).
A total of 6 (7.3%) of the propranolol-treated children and 10 (12.2%) of the control subjects had 
an abnormal ASQ result (P = .292). On underlying ASQ domains no significant differences in 
percentages of children with abnormal scores were found, but numbers were low in both groups 
(Table III). The mean ASQ total score (25th-75th percentile) was 52.9 (50.8-57.0) in the propranolol 
treated group and 51.9 (49.0-56.0) in the control group. Differences in mean ASQ total scores 
between the groups were not significant (P = .383), nor were the differences between the groups 
concerning the mean scores on the underlying ASQ domains (all P > .05). 
There was no significant correlation between the age at the start of propranolol treatment and 
ASQ results (≥ 1 deviant ASQ domain score) (ρ = 0.117; P = .296) or between the duration of 
propranolol treatment and ASQ results (ρ = 0.018; P = .874). There was also no correlation 
between the duration of propranolol treatment and the ASQ total score (ρ = -0.072; P = .519) or 
age at the start of propranolol treatment and the ASQ total score (ρ = -0.119; P = .289).
Mean height and weight of patients with IH treated with propranolol and control subjects did not 
differ (Table IV). 
Finally, in 40.3% of the 72 cases where parents completed the side-effects questionnaire, sleep 
or mood disturbances after the start of propranolol treatment were reported. In 20.8% of the 72 
cases parents reported mood or sleep improvement after discontinuing propranolol. There was 




In this matched case-control study, we found no differences in developmental outcome or growth 
in patients with IH treated with propranolol at the age of 4 years compared with their twin siblings 
or matched control subjects. Sleep and mood disturbances were frequently reported by parents, 
but were not associated with impaired developmental outcome. 
These results improve on our previous study because of the prospective design, matched control 
group, and the use of a validated developmental screening instrument.14 They concur with the 
findings of Gonski and Wargon,22 who found no gross-motor development problems in patients 
with IH treated with propranolol. The discrepancy between our findings and the concerns raised 
by Langley and Pope9 based on studies of adult volunteers may be explained by the plasticity 
of the brains of young children, enabling them to respond in a more dynamic manner to the 
environment than adults.23
We did not find any significant correlations between age at start of treatment or duration of 
treatment and developmental scores. Cases and controls had similar heights and weights at age 
4 years, corresponding with data presented at the 20th Congress of the International Society for 
the Study of Vascular Anomalies in 2014.24 The reason why beta-blockers may impair fetal but 
not infant growth might be explained by an effect on placental blood flow.25 
We did not find a relationship between mood and sleep problems encountered during propranolol 
treatment and developmental outcome. We hypothesize that sleep and mood disturbances, 
although burdensome and worrisome for parents, are not severe enough to cause measurable 
effects on general development.
A strength of our study is that we were able to match cases with controls for many well-known 
confounders associated with developmental delay. Limitations were that we excluded preterm 
children and children born small for gestational age, which limits the generalizability of our 
results.20
It is possible that effects on development, behavior, and executive functioning, including memory 
function, may only become evident at a more advanced age. Nevertheless, our findings that 
growth in propranolol-treated children was similar to control subjects and that mood and sleep 
problems did not affect developmental outcome may facilitate decision making for parents and 
physicians considering the possible risks and benefits of propranolol treatment for IH.
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 (n = 82)
P value a
Female gender 64 (78.0%) 63 (76.8%) .85
Gestational age in weeks  
(25th-75th percentile)
39.1 (38.0-40.0) 39.1 (38.0-40.0) .71
Birth weight in grams (range) 3475 (2130-4785) 3435 (2570-4380) .55
Mean age in months b 
42, 43 or 44 months 
45, 46 or 47 months 










Ethnicity mother  










Education of mother d 
Low 
Low to intermediate 


















a Based on Mann-Whitney U tests (nonparametric data) or Pearson χ2 tests (parametric data).
b At the moment of Ages and Stages Questionnaire assessment.
c One case from New Zealand in propranolol-treated group included in North-European group.
d Low = primary school or less; low to intermediate = low-level technical and vocational training (<12 years 
of education); intermediate to high = high school or medium-level technical and vocational training (12-16 
years of education); high = university or high-level technical and vocational training (>16 years of education).
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table II. Indication of propranolol treatment in children with infantile hemangioma
Primary treatment indication n %
(Impending) visual impairment 39 47.6
Ulceration 22 26.8
Cosmetic risk/facial deformity a 11 13.4
Nutritional problems 4 4.9
Mechanical impairment b 3 3.7
Ulceration risk in near future 2 2.4
(Impending) nasal obstruction/stridor 1 1.2
Total 82 100
a  (Facial) infantile hemangioma deemed to imply a very high risk of psychosocial implications now and in 
the future.
b When size or location of the infantile hemangioma created a restriction in daily functioning. 
table III. Number of children with abnormal 48-months Ages and Stages Questionnaire scores 
Abnormal ASQ a Propranolol-treated  
Ih-children  
(n=82)
Control group  
(n=82)
P value b
Fine motor 1 (1.2%) 4 (4.9%) 0.17
Gross motor 2 (2.4%) 4 (4.9%) 0.41
Communication 1 (1.2%) 1 (1.2%) 1.00
Problem solving 1 (1.2%) 1 (1.2%) 1.00
Personal social functioning 2 (2.4%) 2 (2.4%) 1.00
ASQ, Ages and Stages Questionnaire; IH, infantile hemangioma.
a Abnormal score for ≥ 1 domain.
b Based on χ2 test .
87
4
EffEct of propranolol on dEvElopmEnt and growth
table IV. Mean height and weight at the age of 45 months
Propranolol-treated Ih, 
n = 82 (range)
Control group,     
n = 82 (range)
P value a
height, cm 103,7 (96.0-116.7) 103.6 (93.5-114.5) .982
Weight, kg 16.8 (13.0-21.5) 16.9 (13.2-23.3) .780
IH, Infantile hemangioma.























































Fig 1. Sampling procedure. IH, infantile hemangioma.
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1)  Did your child become more sleepy, drowsy and  Yes  No 
 less active after propranolol-treatment start?
1)  Did your child become more restless during  Yes  No 
sleep after propranolol-treatment start?
1)  Did your child become more active  Yes  No 
after propranolol-treatment stop?
1)  Did your child become less restless  Yes  No 
during sleep after propranolol-treatment stop?
Appendix 1. Questionnaire concerning mood and sleep disturbances
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Concern has been raised about the potential long-term effects of propranolol treatment for 
infantile hemangioma (IH).
objectives
We sought to assess psychologic (social, emotional, behavioral, and executive) functioning in 
children treated with propranolol for IH.
Methods
Twenty-seven patients with IH (6.1-7.6 years of age) treated with propranolol for ≥ 6 months 
during infancy, and without other developmental risk factors, were recruited. Parents completed 
the Behavior Rating Inventory of Executive Function, Social Emotional Questionnaire, Child 
Behavior Checklist, and Strengths and Difficulties Questionnaire. For each questionnaire, the 
number of patients with abnormal scores, based on established cutoff points, was calculated.
Results
Only 1 child (3.7%) scored outside the normal range. The Hemangioma Severity Scale did not 
correlate with psychologic problems in these patients. Longer treatment duration was found to 
correlate with less attention-deficit hyperactivity disorder (ADHD) characteristics (ρ = −0.476; P 
= .012) and better executive functioning (ρ = −0.466; P = .014).
Limitations
Exclusion of children born at gestational age <36 weeks or small for gestational age, no 
reference group and relatively small study size.
Conclusion




EffEct of propranolol on psychological functioning
INtRoDuCtIoN
Propranolol has become first-line treatment for infantile hemangiomas (IHs) with associated 
morbidity.1,2 
Little is known about the long-term effects of propranolol treatment. It has been suggested that 
propranolol could affect the developing central nervous system of infants. Animal studies and 
studies with adult volunteers taking propranolol found possible impairment in forming emotional 
arousing memories.3,4 It is known that long-term suboptimal sleep (a frequently reported side 
effect) may be detrimental to the brain and behavior in young children.5-8 In a retrospective pilot 
study, our group found no negative effect of propranolol treatment during infancy on psychomotor 
development in 103 toddlers at 2 years of age.9 We found no increased developmental risk or 
growth impairment at 4 years of age in 82 patients.10
The objective of the present study was to assess the psychologic (social, emotional, behavioral, 
and executive) functioning of propranolol treated infants at 7 years of age. We also wished to 
explore the correlation between psychologic functioning and hemangioma severity (assessed 
by the Hemangioma Severity Scale [HSS]11), socioeconomic status (SES), age at the start of 
propranolol treatment, and treatment duration.
PAtIeNtS AND MethoDS
Patients
Between September 2015 and February 2016, the parents of 66 children born with IH between 
2008 and 2010 were asked to participate in this prospective study. The inclusion criteria were 1) 
propranolol treatment for ≥ 6 months and 2) age ≥ 6 years at the time of assessment. Children 
with known risk factors for developmental delay or growth restriction, including prematurity 
(< 36 weeks’ gestation), small for gestational age (birthweight ≤10 percentile for gestational 
age on Dutch growth charts), or other major congenital malformations were excluded, as were 
children with relevant comedications during infancy. Fig 1 provides an overview of the sampling 
procedure. The study was approved by the local institutional medical ethical review board.
Methods
Data on gestational age, sex, birth weight, ethnicity, age at the treatment initiation, and treatment 
duration were collected from the medical charts. To assess psychologic functioning, parents 
were asked to complete 4 validated, standardized questionnaires: (1) Child Behavior Checklist 
(CBCL)12 to assess behavioral problems; (2) Strengths and Difficulties Questionnaire (SDQ)13 
to assess emotional and behavioral difficulties; (3) Social Emotional Questionnaire (SEQ)14 
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to assess symptoms of psychopathology exhibited by a child and consisting of 4 subscales: 
attention-deficit hyperactivity disorder (ADHD), autism, problematic social behavior, and anxious/
negative mood; and (4) Behavior Rating Inventory of Executive Function (BRIEF)15 to assess 
executive functioning. The total scores of the BRIEF, CBCL, and SDQ were used and the scores 
on the 4 SEQ subscales (no total score available according to the manual).
The HSS score, based on photographs taken just before propranolol treatment combined with 
data from the medical records, was used to measure the severity of the IH.11 The educational 
level of the mother was determined to assess SES.
Data analysis
For each questionnaire, the number of patients who scored abnormally (defined as the 95th 
or 97.7th and higher percentiles, depending on the specific questionnaire) was calculated. 
The cutoff points were based on the standard Dutch youth population and were sex- and age-
matched (except for the SDQ, which has only general cutoff points). Because of the normal 
distribution of the sample, > 1.6 children (> 5.8%; > 1.5 SD) with an abnormal score on the 
questionnaires would indicate psychologic dysfunction in our cohort. With this assumption, a 
reference cohort was not required.
Spearman rank correlation coefficient (or Pearson correlation coefficient in case of normal 
distribution) was calculated to determine the correlation between the HSS score, SES, age at 
the start and duration of propranolol treatment, and assessment of psychologic functioning. 
Correlation coefficients were considered statistically significant at P < .05.
ReSuLtS
Twenty-seven (49.1%) of 55 eligible patients were recruited for the study (Table I). Treatment 
indications are listed in Table II. Propranolol was started at a mean age of 6.0 months (range, 
1.3-29.0 months; SD 5.5). The mean duration of treatment was 12.3 months (range, 6.0-25.9 
months). 
Only 1 child had an abnormal score on executive functioning (BRIEF), behavioral problems 
(CBCL), emotional and behavioral difficulties (SDQ), and autism (SEQ). No child scored 
abnormally on the other 3 subscales of the SEQ.
Significant correlations were found only between propranolol treatment duration and executive 
functioning (BRIEF) (ρ = −0.466; P = .014) and ADHD characteristics (subscale SEQ) 
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(ρ = −0.476; P = .012); therefore, longer treatment duration correlated with better executive 
function and fewer ADHD characteristics.
DISCuSSIoN
This prospective study found no evidence of psychologic (social, emotional, behavioral, or 
executive) problems in 7-year-old patients who were treated with propranolol for IH. One girl 
scored abnormally on several aspects of psychologic functioning. In an additional interview 
with her parents, we learned that she was diagnosed with pervasive developmental disorder–
not otherwise specified (PDD-NOS) with characteristics of ADHD at 5 years of age, which was 
consistent with the findings of our questionnaires. The family history was positive for autistic 
spectrum disorders, which might better explain the deviant scores than propranolol treatment.
These results strengthen the findings of our previous studies9,10 because of the older age of the 
children and the specific aspects of psychologic school-related functioning that were assessed. 
The concerns raised by Langley and Pope4 were not substantiated. This may be explained by the 
plasticity of the brains of young children, enabling them to respond in a more dynamic manner 
to the environment (eg, exposure to propranolol) than adults.16
Limitations of our study include the fact that we excluded children born preterm or who were 
small for gestational age, which limits the generalizability of our results. A strength is that we 
used a prospective design and included multiple validated questionnaires to assess psychologic 
functioning.
It is possible but unlikely that effects of propranolol on the central nervous system could become 
evident at a later age. Studies using neuropsychologic examination, which is more sensitive 
to detection of potential deviations, including memory functioning, would be of value to further 
assess the long-term safety of propranolol treatment in infancy.
98
Chapter 4.3
table I. Characteristics of children with infantile hemangioma treated with propranolol 
Variable Propranolol-treated Ih children (n = 27)
Female gender 19 (70.4%)
Gestational age in weeks (25th-75th percentile) 39.2 (37.0-41.0)
Mean birthweight in grams (range) 3459 (2130-4275)
Mean age in months a (range) 79.5 (73-91)
Education of mother, b n (%) 
  Low 
  Low to intermediate 







a Age at the time of assessment. 
b  Low = primary school or less; low to intermediate = low-level technical and vocational training (<12 
years of education); intermediate to high = high school or medium-level technical and vocational training 
(12-16 years of education); high = university or high-level technical and vocational training (>16 years of 
education).
 
table II. Indication of propranolol-treatment for children with infantile hemangioma
Primary treatment indication n %
(Impending) visual impairment 10 37.0
Ulceration 9 33.3
Cosmetic risk/facial deformity a 3 11.1
Nutritional problems 1 3.7
Ulceration risk in near future 1 3.7
(Impending) nasal obstruction/stridor 3 11.1
Total 27 100
a  Cosmetic risk/facial deformity: (facial) infantile hemangioma deemed to imply a very high risk of psychosocial 
implications now and in the future.
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Infantile hemangioma (IH) is a benign condition; its course is usually mild and treatment is not 
always needed. However, IH may be accompanied by (impending) severe life- or function-
threatening complications or associations. Moreover, regression of IH is not always complete, 
which must be taken into account if considerations have to be made about whether or not to 
treat. Complications and possible lifelong residual lesions may be prevented by timely referral 
and treatment. Therefore, an active approach should be considered on time and the impact of 
the IH has to be weighed against the impact of treatment.
Since the introduction of propranolol as a therapeutic approach for IH, 10 years ago, with a 
much more favorable safety-efficacy profile than former treatments, its use has been expanded 
rapidly worldwide.14, 15 Propranolol now has a clear place in the therapeutic arsenal for IH and 
has made the condition better treatable and less severe. Unfortunately, this is still insufficiently 
known to some of the potential referrers. Late referrals may cause unnecessary complications 
and/or residual lesions. With propranolol, novel considerations about referral and treatment have 
to be made. 
This thesis provides guidance for this decision-making process, using the data from research 
in a large cohort of IH-patients. To provide more insight, we looked into the impact of IH on 
the Quality of Life (QoL) of children and their parents to give direction to treatment indication; 
we sought for methods to assess the severity of IH in relation to treatment indication; and we 
brought to light the possible long-term effects of propranolol, to facilitate a deliberate choice 
about treatment. The results of these studies will be summarized and discussed below. 
Aim 1: to explore the influence of Ih on the Quality of Life of Ih-patients and 
their parents
Impact of IH is an important reason for whether or not to start therapy. This thesis made the first 
steps in accessing the impact of IH on the QoL in children and their parents, using an IH-specific 
QoL questionnaire. Previously, several studies have tried to measure the impact of IH on children 
and their parents, but results are conflicting, due to the heterogeneity of the questionnaires being 
used (most of them being not IH-specific) and due to the differences between the included 
participants. In chapter 2 a Dutch version of a validated IH-specific Quality of Life questionnaire 
(IH-QoL) was used to investigate the impact of IH on QoL in (parents of) young children.10 The 
QoL of IH-patients and their parents only seemed to be affected mildly (mean score of 22.6 on 
the scale 0-116). QoL was correlated with IH severity as well as visibility (facial location). The 
more severe and/or more visible the IH, the more the QoL was affected negatively. The visibility 
of the IH may be the reason to choose for propranolol treatment, despite the fact that it is not 
a harsh medical treatment indication. These findings are in line with the study of Hoornweg et 
al.8 and Cohen-Barak et al.6 Hoornweg et al. concluded that the majority of children with an IH 
and their parents can live a good life early on, however having a prominent IH, leaving a visible 
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residual lesion on the skin, could result in psychosocial problems later in life. Cohen-Barak et al. 
found that children with IH do not experience a lowered QoL or self-esteem. 
Aim 2: to find a useful tool for propranolol treatment decision
Chapter 3 evaluated the ability of the Hemangioma Severity Scale (HSS)12 to quantify the 
severity of IH and its ability to predict the need for treatment with propranolol. The HSS is user-
friendly and comprehensive compared with other available scoring tools. It consists of objective 
variables, such as IH-size, location, and the presence of established risk factors for systemic 
anomalies and subjective variables, such as pain and risk of disfigurement. We found that 
HSS scores were significantly different in IH-patients who were treated with propranolol versus 
patients who did not receive propranolol treatment (10 vs 7; P < 0.001). In light of the distribution 
of HSS scores in the propranolol and no-propranolol groups, cutoff values of ≥ 11 for indication 
for propranolol treatment and ≤ 6 for no indication for propranolol treatment could be defined. 
This resulted in a specificity of 89% (HSS ≥ 11) and sensitivity of 94% (HSS ≤ 6). With respect 
to the high performance of these two statistical measures, we concluded that the HSS could be 
used as a triage tool for propranolol treatment, empowering less experienced colleagues in their 
decision making for an active approach in IH. In case of HSS score in the so called ‘grey area’ 
between 6 and 11 other factors such as age of the patient, IH-type, and parental preferences 
should be taken into account when making a treatment decision.
Aim 3: to detect the possible long-term effects of propranolol treatment of Ih
In 2015, concern has arisen about possible long term effects of propranolol treatment on the 
development of young children with IH.16 The more knowledge about (long-term) safety, the 
better the decision about whether or not to treat, especially in non-function-threatening but for 
instance clearly visible IH, that may also have an impact on children’s and their families’ lives. 
This thesis strived to make a relevant contribution concerning this topic. In chapter 4.1 the 
possible negative effect of propranolol treatment on the psychomotor development of infants 
with IH (n=103) at mean age of 3 years was evaluated, using the data from the Dutch Well Child 
Preventive Health Care Clinics, reported in the Van Wiechen Scheme (VWS). The VWS consists 
of 3 sections assessing fine motor/adaptation/personal social functioning, communication, 
and gross motor skills. Only 1 child (1%) (95% CI: 0.03%; 5.29%) had an increased risk for 
psychomotor developmental delay based on the VWS results. This was a 3-year-old child of 
immigrant parents. Cultural aspects and a language barrier may have accounted for his delayed 
communication skills. No child was referred to a pediatrician for further evaluation of possible 
psychomotor delay at any stage. In conclusion, no evidence of psychomotor developmental 




Chapter 4.2 compared psychomotor development and growth in 4-year-old children treated 
with propranolol for IH (n = 82) with nontreated healthy controls, using the 48-months Ages and 
Stages Questionnaire (ASQ), a well-known instrument that assesses different developmental 
domains of children: communication, fine motor, gross motor, problem solving and personal-
social functioning. A total of 6 (7.3%) of the propranolol-treated children and 10 (12.2%) of the 
control subjects had an abnormal ASQ total score (P = 0.292). On the specific ASQ domains, 
no significant differences between the propranolol treated IH patients and controls with regard 
to percentages of children with abnormal scores were found. The mean ASQ total score (25 th-
75th percentile) was 52.9 (50.8-57.0) in the propranolol treated group and 51.9 (49.0-56.0) in the 
control group. Differences in mean ASQ total scores between the groups were not significant (P 
= 0.383), nor were the differences between the groups concerning the mean scores on the ASQ 
domains (all P > 0.05). Mean height and weight of patients with IH treated with propranolol and 
control subjects did not differ either. In conclusion, no increased risk for developmental delay or 
growth impairment at the age of 4 years in IH-patients treated with propranolol was found. 
Finally, chapter 4.3 assessed psychological (social, emotional, behavioral, and executive) 
functioning in 7-year-old children (n = 27) treated with propranolol for IH. The following 
standardized, validated questionnaires were used: Behavior Rating Inventory of Executive 
Function (BRIEF), Social Emotional Questionnaire (SEQ), Child Behavior Checklist (CBCL), and 
Strengths and Difficulties Questionnaire (SDQ). Only 1 child (3.7%) scored outside the normal 
range. This girl had an abnormal score on executive functioning (BRIEF), behavioral problems 
(CBCL), emotional and behavioral difficulties (SDQ), and autism (SEQ). In an additional interview 
with her parents, it became clear that she was diagnosed with pervasive developmental disorder–
not otherwise specified (PDD-NOS) with characteristics of ADHD at 5 years of age, which was 
consistent with the findings of our questionnaires. The family history was positive for autistic 
spectrum disorders, which might better explain the deviating scores, than the relationship with 
propranolol. In conclusion, no increased risk for psychologic problems at age 7 was found in 
propranolol treated IH-patients.
General discussion and future perspectives
This thesis brings to light important and relevant topics in the world of IH care. We were able to 
perform several studies on our large cohort of IH-patients in different ages. This cohort was built 
up by gathering data in the daily clinical practice from many IH-patients since 2008, after the 
discovery of the therapeutic value of propranolol. In the past period almost 600 IH-patients have 
been treated with propranolol in our center, providing us valuable experience in IH treatment.
Concerning the QoL, first steps have been made. We found that the impact of an IH on patients 
and their parents was relatively mild at the age of 4.4 months. However, this may (partly) be 
explained by the fact that parents were already (partially) comforted during the first consultation 
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with a physician with specific and extensive experience on IH treatment. It would be interesting 
to assess QoL (and IH-severity) before consulting a specialized physician. 
Regarding the Hemangioma Severity Scale (HSS) as a tool to predict the indication for treatment 
with propranolol, more than first steps have been made. We did not only show the significant 
difference between the HSS-scores in propranolol treated versus the non-treated IH-patients, 
but we also provided cutoff values for treatment. We believe that the HSS could be a useful 
tool for treatment decision. However, the HSS has its limitations as a directive for treatment 
indication, because certain IH-characteristics receive many points within HSS because of 
(serious) associations with anomalies, although these associations/ characteristics do not 
always immediately form a treatment indication. Therefore, we suggest the creation of a new 
triage tool with elements from the HSS, IH-QoL and the inclusion of factors that directly affect 
the choice of treatment, such as age of the patient, IH-type, and parental preferences. In the 
ideal situation, it would be a tool that can be filled in by the parents before consultation with their 
physician. However, it is inevitable that the professional must also fill in part of the score. If such a 
tool will be created, we assume it will consist of two main parts: 1. Part for the parents (subjective 
information, easy to obtain before the consultation) and 2. Part for the professional (objective 
information, but also an estimate of course and residual lesions, filled in during the visit to the 
hospital). In the current digital age, it should take a little effort to create a system able to merge 
both parts, providing a score indicating treatment of the patient.
Finally, in treatment of non-functional and non-life-threatening IH, no health risk can be accepted, 
not on the short term, nor on the long run. In our opinion, concerns about the possible long term 
side effects of propranolol treatment in IH-patients are becoming increasingly less likely due to the 
longitudinal studies we performed, which showed no long-term negative effects of propranolol. 
Our findings are partly in contradiction with the recent study of Mahon et al. 17 who concluded 
that propranolol-treated children may have temporary delayed gross motor development when 
screened at 10-24 months, using the ASQ-3. Twenty five percent of their cohort consisted of 
premature infants, which is higher than the 20% referenced in the literature.18 Unfortunately, no 
comparison between prematures and non-prematures was presented. Interpreting these data, 
we do not agree with the conclusion and statements of the authors, however more longitudinal 
studies are needed to investigate this further. 
In 10 years of our experience, no signs of these long term effects have been registered. However, 
we do believe that it is important to remain critical. Future (prospective) studies using advanced 
neuropsychological tests in school going propranolol treated children, may be of a help to 






This thesis shines a new light on considerations concerning IH treatment, by taking the impact 
of the IH into account, by providing the tools for the appropriate treatment indication and by 
reassuring physicians, patients and their parents concerning the (long term) safety of propranolol. 
Ten years after the first publication in the NEJM by dermatologist dr. Christine Léauté Labrèze, 
we have reached the point that propranolol treatment can also be considered with confidence in 
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Infantiel hemangioom (IH) is een benigne aandoening; het natuurlijke beloop is over het 
algemeen mild en behandeling is dan ook niet altijd noodzakelijk. Echter, een IH kan gepaard 
gaan met (dreigende) ernstige levens- dan wel functiebedreigende complicaties. Bovendien is 
regressie van IH niet altijd volledig. Hiermee dient rekening te worden gehouden wanneer een 
afweging wordt gemaakt over het wel of niet behandelen van een IH. Complicaties en blijvende 
restafwijkingen kunnen mogelijk worden voorkomen door patiënten tijdig te behandelen. 
Hiervoor moet op tijd een actieve aanpak worden overwogen en moet de impact van het IH 
worden afgewogen tegen de impact van de behandeling. 
Sinds de ontdekking van de therapeutische waarde van propranolol voor IH, tien jaar geleden, 
een behandeling met een veel gunstiger veiligheids- en effectiviteitsprofiel vergeleken met 
behandelingen die voorheen werden toegepast, is het gebruik ervan snel wereldwijd verspreid.14, 
15 Op dit moment heeft propranolol een prominente plaats in het therapeutische arsenaal van 
IH. Hierdoor is het IH beter te behandelen en is daardoor ook een minder ernstige aandoening 
geworden. Helaas is dit veranderend therapeutisch beleid niet bij iedere potentiële verwijzer 
bekend. Late verwijzingen kunnen zorgen voor het ontstaan van onnodige (en mogelijk 
vermijdbare) complicaties en/of restlaesies van het IH. Door de komst van propranolol zijn nieuwe 
overwegingen noodzakelijk met betrekking tot het verwijzen en behandelen van patiënten met 
IH. 
Dit proefschrift vormt een leidraad voor dergelijke beslisprocessen, gebruikmakend van data uit 
onderzoeken met een groot cohort IH-patiënten. Door ons onderzoek is meer inzicht verkregen 
over de impact van IH op de kwaliteit van leven (QoL) van kinderen en hun ouders. Dit inzicht 
is belangrijk voor de behandelindicatie. Verder is gezocht naar manieren waarop men de ernst 
van IH kan inschatten in relatie tot behandelindicatie. Tot slot zijn de mogelijke lange termijn 
effecten van propranolol onderzocht met als doel een weloverwogen beslissing te kunnen 
maken aangaande behandelindicatie. Resultaten van deze studies zullen hieronder worden 
bediscussieerd. 
Doel 1: het onderzoeken van de invloed van Ih op de kwaliteit van leven van 
Ih-patiënten en hun ouders
Impact van IH is een belangrijke reden voor het wel of niet starten met de behandeling. Dit 
proefschrift heeft de eerste stappen gezet in het onderzoek naar de impact van IH op de 
kwaliteit van leven (QoL) van kinderen en hun ouders, gebruikmakend van een IH-specifieke 
QoL vragenlijst. In het verleden hebben meerdere studies getracht om de impact van IH op de 
kinderen en hun ouders te bepalen. Helaas zijn de resultaten van deze studies tegenstrijdig door 
de heterogeniteit van de gebruikte vragenlijsten, waarvan de meeste niet IH-specifiek waren, en 
door de verschillen tussen de geïncludeerde deelnemers. In hoofdstuk 2 werd een Nederlandse 
versie van een gevalideerde IH-specifieke vragenlijst over kwaliteit van leven (IH-QoL) gebruikt 
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om de impact van IH op de QoL van (ouders van) jonge kinderen te onderzoeken.10 De QoL 
van IH-patiënten en hun ouders bleek slechts in milde mate te zijn beïnvloed (gemiddelde 
score van 22.6 op de schaal van 0-116). De QoL had een correlatie met de ernst van IH en de 
zichtbaarheid (lokalisatie in het gelaat) ervan. Hoe ernstiger en/of zichtbaarder het IH, des te 
groter de negatieve invloed op de QoL. De zichtbaarheid van IH kan een reden zijn om voor de 
behandeling te kiezen, ondanks het feit dat er geen harde medische behandelindicatie bestaat. 
Deze bevindingen zijn vergelijkbaar met de bevindingen van Hoornweg et al.8 en Cohen-Barak 
et al.6 Hoornweg et al. concludeerden in hun studie dat de meerderheid van kinderen met IH en 
hun ouders een goed leven kan leiden. Het hebben van een prominent IH, dat mogelijk ook een 
zichtbare restlaesie achterlaat, kan later in het leven wel voor psychosociale problemen zorgen. 
Cohen-Barak et al. hebben in hun studie vastgesteld dat kinderen met IH geen slechtere QoL of 
een negatief zelfbeeld hebben.
Doel 2: het vinden van een instrument om een behandelindicatie te 
voorspellen
In hoofdstuk 3 is er gekeken of de zogenaamde Hemangioma Severity Scale (HSS)12 waarmee 
de ernst van het IH kan worden gekwantificeerd, ook de behandeling met propranolol kan 
voorspellen. De HSS is een uitgebreid en gebruiksvriendelijk instrument, vergeleken met andere 
beschikbare instrumenten. Het bestaat uit objectieve variabelen zoals grootte van het IH, 
lokalisatie en de aanwezigheid van eventuele risicofactoren voor associaties met systemische 
anomalieën en uit subjectieve variabelen als pijn en risico op deformatie. We hebben vastgesteld 
dat HSS-scores significant verschilden bij IH-patiënten die met propranolol waren behandeld, 
vergeleken met de niet behandelde patiënten (10 vs 7; P < 0.001). In het licht van de distributie 
van HSS-scores in de propranolol en niet-propranolol groepen konden er afkapwaardes worden 
vastgesteld. Een HSS-score van ≥ 11 gaf veelal een indicatie voor behandeling met propranolol. 
Een HSS-score van ≤ 6 impliceerde juist dat er geen indicatie was voor behandeling met 
propranolol. Deze afkapwaardes zorgen voor de specificiteit van 89% (HSS ≥ 11) en sensitiviteit 
van 94% (HSS ≤ 6). Gezien deze hoge specificiteit en sensitiviteit concludeerden we dat de HSS 
kan worden gebruikt als een triage-instrument voor propranolol behandeling en op deze manier 
ook minder ervaren collega’s kan helpen in de beslissing omtrent wel of niet behandelen van het 
IH. In het geval dat de HSS-score binnen het zogenaamde ‘grijze gebied’ valt (score tussen 7 en 
10) zullen andere factoren als leeftijd van de patiënt, IH-type en de voorkeur van ouders mede 
gewogen moeten worden om een weloverwogen beslissing te kunnen maken.
Doel 3: het detecteren van de mogelijke lange termijn effecten van 
propranolol behandeling voor Ih
In 2015 zijn er zorgen geuit met betrekking tot de mogelijke lange termijn effecten van propranolol 
behandeling op de ontwikkeling van jonge kinderen met IH.16 Hoe meer we weten over de (lange 




van de niet functiebedreigende maar bijvoorbeeld wél duidelijk zichtbare IH die juist ook een 
impact kunnen hebben op de kwaliteit van leven van de kinderen en hun familieleden. In dit 
proefschrift hebben we een poging gedaan een relevante bijdrage te kunnen leveren in deze 
kwestie. 
In hoofdstuk 4.1 werd het mogelijke effect van propranolol behandeling op de psychomotore 
ontwikkeling van de kinderen met IH (n = 103) met een gemiddelde leeftijd van 3 jaar geëvalueerd 
door het gebruik van data van de consultatiebureaus die werden gerapporteerd in het Van 
Wiechen Schema (VWS). Het VWS bestaat uit 3 onderdelen: fijne motoriek/adaptatie/persoonlijk 
en sociaal functioneren, communicatie en grove motoriek. Slechts 1 kind (1%) (95% BI: 0.03%; 
5.29%) had een toegenomen risico op een vertraagde psychomotore ontwikkeling gebaseerd 
op de resultaten van VWS. Het betrof een 3 jaar oud kind uit een immigrantengezin. Culturele 
aspecten en taalbarrière zouden een rol gespeeld kunnen hebben bij de vertraagde ontwikkeling 
van communicatieve vaardigheden van dit kind. Geen enkel onderzocht kind is verwezen naar 
de kinderarts voor aanvullend onderzoek op basis van de gegevens van het VWS. Concluderend 
zagen we geen aanwijzingen voor invloed van propranolol op psychomotore ontwikkeling bij de 
kinderen met IH die behandeld waren met propranolol.
hoofdstuk 4.2 vergelijkt de psychomotore ontwikkeling en groei van kinderen met IH die 
met propranolol zijn behandeld (n = 82) met gezonde kinderen die geen propranolol hebben 
gehad. Er werd gebruikgemaakt van de 48-maanden Ages and Stages Questionnaire (ASQ), 
een bekend instrument om verschillende ontwikkelingsdomeinen van kinderen te bepalen: 
communicatie, fijne motoriek, grove motoriek, probleemoplossend vermogen en persoonlijk-
sociaal functioneren. In totaal hadden 6 kinderen (7.3%) die behandeld waren met propranolol 
en 10 controles (12.2%) een afwijkende ASQ totaalscore (P = 0.292). Verder zijn per specifiek 
domein van de ASQ geen significante verschillen gevonden met betrekking tot de percentages 
van kinderen met afwijkende scores. Het gemiddelde ASQ totaalscore (25ste-75ste percentiel) 
was 52.9 (50.8-57.0) in de groep die was behandeld met propranolol en 51.9 (49.0-56.0) in de 
controlegroep. Verschillen in gemiddelde ASQ totaalscores waren niet significant tussen de beide 
groepen (P = 0.383). Ook waren er geen significante verschillen met betrekking tot gemiddelde 
ASQ scores voor elk afzonderlijk ASQ domein (alle P > 0.05). Gemiddelde lichaamslengte en 
-gewicht van patiënten met IH die met propranolol waren behandeld verschilden evenmin met 
die van de controlegroep. Concluderend hebben we geen verhoogde risico op vertraagde 
ontwikkeling of groeiproblematiek vastgesteld bij kinderen van 4 jaar oud die behandeld waren 
met propranolol voor hun IH. 
Tot slot, hoofdstuk 4.3 onderzocht het psychologische (sociale, emotionele, gedragsmatige en 
executieve) functioneren van 7 jaar oude kinderen (n = 27) die met propranolol zijn behandeld 
voor hun IH. De volgende gestandaardiseerde vragenlijsten werden gebruikt: Behavior Rating 
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Inventory of Executive Function (BRIEF), Social Emotional Questionnaire (SEQ), Child Behavior 
Checklist (CBCL), and Strengths and Difficulties Questionnaire (SDQ). Slechts 1 kind (3.7%) 
scoorde buiten het normale bereik. Dit meisje had een afwijkende score op de executieve 
functies (BRIEF), gedragsproblemen (CBCL), emotionele en gedragsmoeilijkheden (SDQ) en 
autisme (SEQ). In een aanvullend interview met haar ouders werd duidelijk dat het kind op de 
leeftijd van 5 jaar was gediagnosticeerd met pervasive developmental disorder–not otherwise 
specified (PDD-NOS) met karaktereigenschappen van ADHD. Deze diagnose paste precies 
in het kader van de door ons gevonden afwijkingen. De familieanamnese was positief voor 
autismespectrum stoornissen, wat een betere verklaring lijkt voor de afwijkende scores van het 
kind dan de mogelijke relatie met propranolol gebruik . Concluderend, is er geen verhoogd risico 
gevonden voor psychologische problemen bij kinderen van 7 jaar oud die behandeld zijn met 
propranolol voor hun IH.
Algemene discussie en toekomstperspectieven
Dit proefschrift brengt verschillende onderwerpen aan het licht aangaande de behandeling 
van IH. Inmiddels zijn binnen de Hecovan-werkgroep bijna 600 IH-patiënten behandeld met 
propranolol; dit geeft een schat aan kennis en ervaring over dit thema. Studies konden worden 
uitgevoerd in dit grote cohort dat werd opgebouwd sinds 2008, toen de therapeutische waarde 
van propranolol voor het eerst aan het licht kwam.
Wat betreft de kwaliteit van leven (QoL), zijn eerste stappen gezet. We hebben laten zien dat 
de impact van een IH op de patiënten en hun ouders mild lijkt op de leeftijd van 4.4 maanden. 
Dit zou (deels) verklaard kunnen worden door het feit dat de ouders reeds (voor een gedeelte) 
gerustgesteld waren tijdens hun eerste gesprek met de arts met specifieke en omvangrijke 
ervaring aangaande IH. Het zou interessant zijn om de QoL (en de IH-ernst) te bepalen vóórdat 
de ouders een gespecialiseerde arts hebben gesproken.
Wat betreft de Hemangioma Severity Scale (HSS) als een instrument om behandeling met 
propranolol te kunnen voorspellen, hebben we meer gedaan dan alleen de eerste stappen zetten. 
We hebben niet alleen laten zien dat er een significant verschil bestaat tussen de HSS-scores 
van de met propranolol behandelde IH-patiënten en de niet behandelde controlepatiënten, 
maar we hebben ook de afkapwaardes vast kunnen stellen die een behandelindicatie kunnen 
voorspellen. We menen dat de HSS een nuttig instrument kan zijn voor de behandelbeslissing. 
Echter, de HSS heeft ook bemerkingen. Enkele IH-karakteristieken zorgen voor hogere HSS-
scores omdat deze de kans op geassocieerde anomalieën vergroten. Deze associaties hoeven 
echter niet direct een behandelindicatie te geven. Derhalve suggereren wij de ontwikkeling van 
een nieuw triage instrument dat zowel elementen van de HSS bevat alsook rekening houdt met 
impact op QoL en andere factoren die van invloed kunnen zijn voor de behandelindicatie, zoals 




instrument zijn dat door de ouders ingevuld kan worden vóór het eerste bezoek aan de arts. 
Echter, het is niet te voorkomen dat de professional ook een deel van een vragenlijst moet 
invullen. Mocht een dergelijk instrument worden ontworpen, dan denken we dat het uit twee 
onderdelen zou kunnen bestaan: 1. Het onderdeel voor de ouders (subjectieve informatie die 
makkelijk te verkrijgen is vóór het eerste bezoek aan de professional) en 2. Het onderdeel voor 
de professional (objectieve informatie, maar ook een inschatting van de uiteindelijke restlaesie 
na de involutiefase), die beide tijdens het eerste consult ingevuld dienen te worden. In de huidige 
digitale tijdperk zou het weinig moeite hoeven te kosten om een systeem te ontwerpen dat 
beide onderdelen kan samenvoegen tot één geheel en een score voor behandelindicatie kan 
berekenen.
Tot slot: in behandeling van niet functie- of levensbedreigende IH mag er geen gezondheidsrisico 
worden gelopen, niet op korte maar ook niet op de lange termijn. Wij zijn van mening dat de zorgen 
over de mogelijke lange termijn effecten van propranolol behandeling van IH-patiënten steeds 
minder gegrond zijn door de longitudinale studies die wij hebben uitgevoerd. Ons onderzoek 
laat zien dat propranolol geen negatieve lange termijn effecten heeft. Onze bevindingen zijn 
gedeeltelijk in strijd met de recente bevindingen van Mahon et al.17 die hebben geconcludeerd dat 
met propranolol behandelde IH-patiëntjes een voorbijgaande vertraging in hun grove motoriek 
kunnen tonen op de leeftijd van 10-24 maanden. Mahon et al. hebben hiervoor gebruik gemaakt 
van de ASQ-3 vragenlijst. Vijfentwintig procent van hun cohort bestond echter uit prematuur 
geboren kinderen18 en bij de analyse is geen onderscheid gemaakt tussen de premature en de 
à-terme geboren kinderen. Dat maakt de resultaten minder betrouwbaar. Nieuwe longitudinale 
studies zijn nodig om dit verder te onderzoeken.
In de tien jaar ervaring met propranolol hebben we geen tekenen van dergelijke lange termijn 
effecten gevonden. We denken echter wel dat het belangrijk is om kritisch te blijven. Toekomstige 
studies met geavanceerde neuropsychologische testen bij schoolgaande, met propranolol 
behandelde kinderen met IH zijn nodig om ouders en artsen nog verder te kunnen geruststellen 
aangaande lange termijn gezondheidsrisico’s door propranolol behandeling.
uiteindelijke conclusie
Dit proefschrift werpt nieuw licht op overwegingen met betrekking tot behandeling van IH, door 
rekening te houden met de impact van IH, door instrumenten te verschaffen ten behoeve van 
behandelindicatie en door artsen, patiënten en hun ouders gerust te stellen wat betreft de 
mogelijke (lange termijn) effecten van propranolol. Tien jaar na de eerste publicatie in de NEJM 
van dermatologe dr. Christine Léauté Labrèze, hebben we een punt bereikt dat propranolol 
behandeling ook kan worden overwogen bij patiënten met niet functiebedreigende, maar wél 
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“Human beings are capable of virtually limitless degradation; they are also capable of virtually 
limitless improvement and achievement. Success depends on goals and on diligence in pursuing 
them.” (Mas Oyama)
Het is eindelijk zo ver. Mijn proefschrift is af! De zware jaren van nachtwerk en weekendwerk 
tussen de slaapjes van mijn zoontjes door zijn eindelijk voorbij. Dit heb ik gelukkig niet helemaal 
alleen hoeven te doen. Zonder de steun van velen was dit proefschrift nooit een feit geworden. 
In het bijzonder wil ik graag de volgende personen bedanken:
Dr. C.J.M. van der Vleuten, beste Carine; jij hebt mij als student bij de hand genomen en 
nooit meer losgelaten. Ik mag echt van geluk spreken dat ik jou ben tegengekomen op mijn 
levenspad op weg naar mijn specialisatie. Collega-onderzoekers waren altijd zo jaloers dat jij 
mijn stukken meestal binnen 24uur nakeek en voorzag van commentaar en verbeterpunten. 
Promotie doen naast een fulltime baan is pittig. Promotie doen met zo’n toegewijde copromotor 
als jij is een makkie. Bedankt voor je eindeloze geduld en voor het feit dat jij mij nooit hebt 
afgerekend op zo veel slordigheidsfouten, dubbele spaties en typo’s. Het lukte jou iedere keer 
opnieuw om van mijn grove (nacht)werk mooie diamantjes te slijpen en de stukken aan het beste 
dermatologische tijdschrift van de wereld te verkopen. Eerlijk is eerlijk, zonder jou was geen 
enkel artikel gepubliceerd geweest. En ik vermoed dat ik zonder jouw hulp en vertrouwen ook 
nooit een opleidingsplek had gekregen, al zou jij dat zelf nooit toegeven. Mijn grote dank voor 
alle deuren die jij voor mij hebt geopend!
Dr. S. Spillekom-van Koulil, beste Saskia; wat heb ik genoten van het werken met jou! Jij bent 
de engel op mijn schouder. Iedere keer dat ik probeerde om de weg van de minste weerstand 
in te slaan, liet jij mij inzien dat het op langere termijn kan lonen om er juist iets meer moeite 
in te stoppen. Vanaf dag één kon ik helemaal eerlijk met je zijn. En wat heerlijk dat jij naast 
mijn copromotor ook een psychologe bent. Lekker bij Saskia langslopen om onderzoeksdata te 
bespreken, op de comfortabele patiëntenstoel belanden en (spreekwoordelijk) uithuilen over de 
verschrikkelijke perifere stage, slapeloze nachten met huilende kindjes en vervelende reviewers 
die zichzelf en elkaar tegenspreken.
Prof. dr. dr. P.C.M. van de Kerkhof, beste professor; bedankt voor uw vertrouwen in mij. Ik kan het 
mij als de dag van vandaag herinneren dat ik bij u in de kamer zat en een fulltime promotietraject 
over psoriasis heb afgewezen. Mijn voorstel was om te gaan werken als ANIOS (en hopelijk later 
als AIOS) en naast het klinische werk promotie te gaan doen met dr. van der Vleuten. We hadden 
toen een deal gesloten waaraan ik bij dezen heb voldaan!
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Prof. dr. L.J. Schultze Kool, beste professor; dank voor uw vertrouwen.
Dr. E. Engwerda (paranimf), lieve Elsemiekje; jij hebt mij zo enorm geholpen. Al deze jaren was 
jij mijn persoonlijke statisticus, mijn SPSS goeroe, mijn rekengodin. Ik weet nog heel goed dat ik 
jou voor de grap opbelde en zei dat jij mij ad hoc moest komen helpen met SPSS. En jawel hoor, 
ondanks dat je op dat moment met iets anders bezig was, was jij bereid om binnen 15 minuutjes 
voor mijn deur te staan voor al het rekenwerk. Wat jammer dat de rol van paranimf tegenwoordig 
slechts ceremonieel is. Mocht ik tijdens mijn verdediging een vraag krijgen over de statistiek, 
dan hoop ik dat jij mij stiekem in mijn oor gaat fluisteren. Elsemiekje, ik ben zo blij dat jij tot de 
beste vriendinnen van mijn vrouw behoort en ik inmiddels jou ook tot een goede vriendin van mij 
kan rekenen! Sinds kort weet ik dat jij mama wordt. Dit betekent in de toekomst gezamenlijke 
kinderfeestjes en elkaar veel vaker zien!
Talip Polat (paranimf), mijn beste vriend; ik vind het zo jammer dat wij elkaar slechts weinig 
zien tegenwoordig. Jij bent eigenlijk mijn appvriend geworden. Er is echter één ding wat jou 
onderscheidt van al mijn andere vrienden, kennissen, collegas. Talip, op mijn familie na ben jij 
de enige waarvan ik niet twijfel dat jij alles aan de kant zou zetten als ik jou nodig zou hebben. Ik 
hoop dat jij beseft dat ik hetzelfde voor jou zou doen. Jij bent sinds kort afgestudeerd als arts. De 
mogelijkheden zijn eindeloos. Welke richting jij ook op zal gaan, jij wordt een geweldige dokter! 
Talipje, ik kan niet wachten tot ik jouw kindjes kan vasthouden. Jij wordt een geweldige vader.
Lieke van Vugt en dr. K. Nguyen, mijn onderzoekmatties; wie had het ooit gedacht dat ik 
vrouwelijke vriendinnen kan hebben. Bedankt dat jullie mijn (vaak hele slechte) grappen kunnen 
waarderen of op zijn minst weten te negeren. Het halve jaartje dat wij samen in één kamer 
hebben gezeten waren supertof. Lieve Kim, als je goed kijkt dan zul je zien dat mijn proefschrift 
qua lay-out een kopietje is van die van jou. Mijn dank voor het goede voorbeeld en het helpen 
met de laatste loodjes van mijn promotie. Lieve Lieke, de dag dat jij aangenomen wordt als AIOS 
dermatologie gaan wij een groot feest vieren. De dag dat jij dermatoloog wordt ga ik mijn best 
doen om jou daar te krijgen waar ik op dat moment werk. 
Daan Smulders (paranimf) en Diebrecht Appelen, mijn kamergenoten en inmiddels ook mijn 
goede vrienden; Bedankt voor de leuke tijd die wij samen hadden, hebben en nog zullen gaan 
krijgen. Bedankt voor de pauzes waarin wij samen gingen gamen, voor de werkgerelateerde 
discussies en voor de spontane biertjes na het werk, waarbij er rekening werd gehouden met het 
feit dat ik vroeg naar huis moest voor mijn kindjes. 
Guan Schellekens, Willem Hubers, Bart Kruize en Tom van Tilborg, mijn vrienden. We kennen 
elkaar al vanaf de middelbare school, vanaf het moment dat ik met een bijna kaalgeschoren 
hoofd, een lange kuif en in een trainingspak aan jullie geïntroduceerd werd door meneer 
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Benneker. Ik was helemaal nieuw op deze school en kon nog niet zo goed Nederlands spreken. 
Jullie hebben mij kennis laten maken met Nederland, het land waar ik zo enorm van houd. 
Jullie hebben mij frikandellen speciaal leren waarderen en mij aangemoedigd toen ik mijn eerste 
kaassoufflé ging bestellen in het Nederlands. Jullie hebben mij zien veranderen van een jochie 
dat dacht dat hij stoer was in de man die ik nu ben. Jullie zijn alle vier zo anders qua karakter, 
uiterlijk en professie. En toch vormen wij samen de meest hechte vriendengroep die er bestaat. 
Guan, ik waardeer jouw enorme doorzettingsvermogen in de harde wereld van business en het 
bankwezen. Jij bent altijd op zoek naar méér, een echte avonturier. Bijzonder hoe jij het steeds 
voor elkaar krijgt om elke vakantie bijna dood te gaan. De ene keer door een olifant die jou 
wil vertrappen, de andere keer door een gevaarlijke plant in de jungle, dan weer wat simpels 
zoals een man die met een shoarma mes achter je aanzit in Bulgarije. Willem, jij bent de meest 
positieve persoon die ik ken op deze aarde. Weet jij überhaupt wat het is om verdrietig te zijn? 
Kon ik maar alles zo goed relativeren als jij. De vrouw die op jouw pad zal komen, zal in de 
zevende hemel belanden! Mits jij je bachelor party overleeft, want ze worden steeds extremer. 
Bartje, mijn kameraad. Ik blijf tegen mensen vertellen dat ik een vriend heb die econometrist is. 
Wat jij precies doet is lastig om uit te leggen en te begrijpen. Iets met economie en rekenen en 
heel erg moeilijk. Ik ben zo blij dat ik jou mag rekenen tot mijn vrienden. Ik kan niet wachten tot 
ik op jouw bruiloft kan dansen. Wie weet wordt het net zo gezellig als mijn bruiloft en kom ik ook 
een keer met een gescheurde broek thuis in plaats van andersom. Tom, onze kennismaking was 
minder warm dan met de rest van de vriendengroep. Jij was degene die pennen en potloden 
tegen mijn hoofd gooide tijdens de lessen Latijn waarna ik jou netjes heb gevraagd of jij direct 
dood wilde of na de les. Toen jij directe actie wenste, heb ik jou bewust laten teleurstellen en je 
dood uitgesteld tot later. En kijk nu dan. Jij bent een van mijn beste maten ooit en dat zal jij altijd 
blijven. Wil jij mij een ding beloven? Gooi alsjeblieft niets naar me tijdens de verdediging, ok?
Kelly Klingenberg, Laura van Tilborg-Suijkerbuik en Dipti Rao, mijn lieve vriendinnen, allemaal als 
‘aanhang’ geïntroduceerd maar inmiddels alle drie echte vriendinnen geworden. Zo fijn om te 
zien dat mijn vrienden zulke lieve en knappe vrouwen hebben. 
Alle arts-assistenten (in het bijzonder Romy, Anke en Wendelien); bedankt voor jullie collegialiteit 
en gezelligheid op de werkvloer, maar juist ook daarbuiten.
Ouders van patientjes met IHs die bereid waren mee te werken aan het onderzoek; heel erg 
bedankt. Jullie zijn echte toppers. Naast een drukke baan en jonge kinderen hebben jullie toch 
nog ergens de tijd vandaan gehaald om mijn saaie vragenlijsten te beantwoorden. 
Mijn lieve mama, papa en broer Evgeni; ik ben opgegroeid badend in liefde en geluk. 
Hoe slecht de omstandigheden ook waren, ik heb een ongelofelijk goede jeugd gehad 




Мамуля, ты самая лучшая мама на свете. Я тебя очень сильно люблю. Мне так радостно 
на душе когда я вижу как сильно твои внуки тебя любят. Так же сильно как и мы любили 
твою маму. Мама, ты святой человек. Я никогда не встречал человека у которого 
есть столько любви и энергии к своим детям и внукам. Папик, мой самый любимый 
и хороший! Я так часто думал о тебе когда писал эту книгу. Я вспоминал твои слова 
что работать врачом можно ещё много лет. И как бы ты сильно не старался, как бы 
ты не потел, но никогда ты дальше не прорвёшься если нету багажа научных работ. Я 
послушал тебя папик, и вот я наконец то стал доктором наук как и мой старшый брат! 
Брат, Женя, за тобой мне не успеть но я стараюсь как могу чтобы хоть чуток быть таким 
же умным как и ты. Теперь мы оба доктора наук! Будь счастливым брат и береги свою 
жену, Женю. Она у тебя просто золото!
 
Mijn lieve Denis en Sem, mijn knappe zoontjes; Het spijt mij, mijn lieve mannetjes, dat papa vaak 
aan zijn promotie zat te werken in plaats van te spelen of te wandelen met jullie. Jullie zijn voor 
mij de allerbelangrijkste mensjes op aarde. Papa is bereid om alles weg te geven als jullie beiden 
maar gelukkig zijn. Niets is voor mij zo kostbaar als de lach op jullie gezichtjes!
Esma Nadi-Moyakine, mijn knappe en lieve vrouw; zonder jou was er geen enkel artikel van dit 
proefschrift gepubliceerd. Zonder jou had ik het nooit kunnen volhouden. Al 11 jaar lang, sinds 
ik jou ken, ben jij het licht in mijn leven. Ik kan mij geen betere levenspartner bedenken en ik kan 
mijn kindjes geen betere moeder wensen dan jou. Er bestaat geen vrouw op aarde die jou ooit 
zou kunnen vervangen. Wij zijn letterlijk de tegenpolen van elkaar qua karakter; ik ben een – en 
jij een +; nog nooit ben ik een plusje tegengekomen die zo veel aantrekkingskracht op mij had 




Met gepaste trots mogen wij ook nog een woord van lof over André schrijven. Ondanks dat hij 
onderzoek doen initieel niet zag zitten, heeft hij toch een prachtig proefschrift afgeleverd. Dit in 
combinatie met zijn gezin en zijn huidige AIOS functie, chapeau! Doorzetten is echter niet de enige 
kwaliteit van André. Naast zijn werk houdt hij namelijk ook erg van sporten, met zijn karate skills 
laat hij geen watermeloen ongeschonden en de vele fitness selfies worden daarnaast veelvuldig 
gedeeld. Na het werken en sporten maakt André graag tijd vrij voor een biertje met vrienden, 
waarbij vanaf een bepaald promillage, enkele mooie nachtelijke avonturen zijn ondernomen. Met 
zijn bijzondere gevoel voor humor ben je sowieso van een geslaagde avond verzekerd! De 
vele anekdotes, ‘Dilemma op dinsdag(en)’ en weddenschappen zijn eenieder wel bekend en 
wisselen zich in een hoog tempo af. Naast humor en sportiviteit heeft André nog een bijzonder 
goede karaktereigenschap: voor zijn vrienden gaat hij door het vuur. Al sta je midden in de 
nacht ergens in the middle of nowhere, André zou je komen halen en geen slecht woord zal hij 
vervolgens over je praten. Naast zijn vrienden is ook zijn gezin belangrijk: zijn 2 prachtige zoons 
en zijn lieve vrouw staan bij André op nummer één.
Al met al zijn wij enorm trots op onze goede vriend en collega, hij heeft de titel van 









ADHD  attention-deficit hyperactivity disorder 
ASQ  Ages and Stages Questionnaire 
BRIEF  Behavior Rating Inventory of Executive Function 
CBCL  Child Behavior Checklist 
CPS child physical symptoms
CSI  child social interactions
D-IH-QoL  Dutch infantile hemangioma specific quality of life questionnaire         
EPCs   endothelial progenitor cells 
GLUT-1  glucose transporter protein type 1 
HAS  Hemangioma Activity Score
HSS  Hemangioma Severity Scale
IGF-2  insulin-like growth factor 2 
IH  infantile hemangioma
IHs  infantile hemangiomas
IH-QoL  infantile hemangioma specific quality of life questionnaire 
ISSVA  International Society for the Study of Vascular Anomalies 
LOLLIPOP  Longitudinal Preterm Outcome Project 
LUMBAR   lower body hemangioma and other cutaneous defects, urogenital anomalies, 
ulceration, myelopathy, bony deformities, anorectal anomalies, arterial 
anomalies, and renal anomalies
mTOR  mammalian target of rapamycin 
OR  odds ratio
PDL  Pulsed dye laser
PEDS  Parents Evaluation of Developmental Status 
PEF  parent emotional functioning
PELVIS   Perineal hemangioma, External genitalia malformations, 
Lipomyelomeningocele, Vesicorenal abnormalities, Imperforate anus, and 
Skin tag
PHACE(S)   posterior fossa anomalies, hemangioma, arterial lesions, cardiac 
abnormalities/coarctation of the aorta, and eye anomalies (sternal cleft or 
supraumbilical raphe)
PPF  parent psychosocial functioning
QoL  Quality of Life        
RAS  renin–angiotensin system 
SACRAL   Spinal dysraphism, Anogenital, Cutaneous, Renal and urologic anomalies, 
associated with an Angioma of Lumbosacral localization 
SDQ   Strengths and Difficulties Questionnaire 
SEQ   Social Emotional Questionnaire
SES   socioeconomic status 
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VEGF    vascular endothelial growth factor 
VWS  Van Wiechen Scheme 
WCPHCC  Well Child Preventive Health Care Clinics 
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